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SERUM VISFATIN- A NOVEL MARKER OF CHRONIC KIDNEY 
DISEASE 
BACKGROUND 
Chronic Kidney Disease (CKD) is  defined  as Glomerular Filteration Rate < 
60ml/min/1.73m
2
 for a minimum of  3 months irrespective of the cause. 
Accelerated atherosclerosis is the main cause of morbidity and mortality in CKD 
patients. Visfatin is  a 52KDa protein predominantly secreted by the visceral 
adipose tissue which  has  anti-inflammatory , Insulin-mimetic and antiapoptotic 
activities.   
AIMS AND OBJECTIVE 
To estimate  the levels of serum Visfatin in patients with CKD and to 
compare it with serum hsCRP (high sensitive C reactive protein), Ccr( Creatinine 
clearance)  and lipid profile.  
MATERIALS AND METHODS 
The study was conducted at Thanjavur Medical College Hospital . 50 
patients of CKD   as cases and 50 age and gender matched healthy individuals 
were selected as cases and  controls respectively.Serum  Visfatin  and Serum 
hsCRP  were estimated  by Enzyme Immune Assay and  Immunoturbidimetric 
method respectively. Serum Total  Cholesterol ( TC),  Triglycerides (TGL) , Very 
Low Density Lipoprotein(VLDL-C), High Density Lipoprotein (HDL-C) were 
estimated by enzymatic method. Creatinine Clearance ( Ccr)and  Low  Density 
Lipoprotein (LDL-C)  were calculated using formula. 
RESULTS 
The mean value of Visfatin in cases  and controls were 27.42±8.92 and 
10.62±1.57  ng/ml (t=13.11; p<0.05 significant) respectively. The level of serum 
visfatin is inversely correlated with Ccr (r= -0.898; p< 0.01) .  Serum hsCRP, TGL 
and VLDL-C were significantly increased and HDL-C was significantly  decreased  
in cases when compared to controls (p < 0.05).There is no significant difference of 
TC between cases and controls .  
CONCLUSION 
 The present study demonstrated that serum Visfatin levels are significantly 
increased in patients with CKD. This increase in serum Visfatin level is 
progressive from the early stages to the late stages of CKD . 
 Visfatin may be considered as the novel marker of mortality predictor in 
CKD patients. Higher the visfatin level, higher the mortality of CKD 
patients. 
Key words 
Chronic kidney disease,  glomerular filteration rate,  Visfatin, high sensitive 
C reactive protein. 
      
INTRODUCTION 
 
Chronic Kidney Disease (CKD) encompasses a spectrum of different 
pathophysiologic processes associated with abnormal kidney function and a 
progressive decline in Glomerular Filteration Rate (GFR)
1
. CKD is defined as 
kidney damage or GFR < 60ml/min/1.73m
2
 for a minimum of 3 months 
irrespective of the cause. The GFR is defined as the rate of plasma flow filtered 
across the glomerular basement membrane .CKD is a growing public health 
problem worldwide with increasing prevalence, high cost and poor outcomes 
like End Stage Renal Disease (ESRD), Cardio Vascular Disease (CVD) and 
Premature Death
2
. 
CKD affects 10-15% of general adult population in developed countries. 
In India, the prevalence of CKD is 0.79%
3
. It is an underestimate of the disease 
because most of the CKD patients die of CVD than to reach ESRD. CKD is the 
12
th
 cause of death and 17
th
 cause of disability worldwide
4
. 
Accelerated atherosclerosis is the main cause of premature morbidity and 
mortality in patients with CKD. Over 80-90% of patients with CKD die 
primarily of CVD before reaching the need for dialysis. This necessitates the 
importance of early detection of CVD before the patient reach advanced stages 
of CKD
5
. 
Eventhough the traditional cardiovascular risk factors such as Diabetes 
Mellitus(DM) , Hypertension(HT) , Smoking and Dyslipidemia are highly 
      
prevalent in CKD patients, they only partly explain the high cardiovascular risk 
of CKD patients. Nontraditional risk factors such as Inflammation, Endothelial 
dysfunction , Insulin resistance and Myocardial necrosis have also been 
associated with the increased cardiovascular event rates and mortality risk in 
CKD patients. 
CKD is associated with chronic inflammation which promotes endothelial 
dysfunction , vascular remodelling and progression of atherosclerosis. In CKD , 
there is a progressive deterioration of renal function may also lead onto 
accumulation of uremic toxins and dyslipidemia which in turn stimulate 
inflammation and result in atherosclerosis
6
. The causes of inflammation among 
patients with CKD are complex and multifactorial
7
. 
Adipose tissue is no more considered as inert site of nutrient storage but 
rather a metabolically active site capable of producing soluble factors called 
Adipokines. Visfatin is one of the adipokine being the subject of intense 
research nowadays because of its pleiotropic actions
8,9
. Most important action is 
acting as a proinflammatory cytokine that stimulates the expression of 
inflammatory cytokines like IL (Interleukin) - 6, Tumour Necrosis Factor (TNF) 
α and β. 
Because of the reduced renal function in CKD patients there will be 
accumulation of these inflammatory cytokines. In CKD there exists an active 
interplay between atherosclerosis and inflammation through the accumulation of 
these inflammatory cytokines. This in turn contributes to the development of 
      
CVD in CKD. So measurement of serum level of Visfatin could therefore have 
a potential value to predict premature atherosclerosis and hence to assess the 
cardiovascular risk in CKD. 
Hence in the present study the serum level of Visfatin is estimated in 
patients with different stages of CKD and the relationship between serum 
Visfatin, inflammation and dyslipidemia were analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
REVIEW OF LITERATURE 
The kidneys play a central role in the homeostatic mechanisms of the 
human body, and reduced renal function strongly correlates with increasing 
morbidity and mortality. 
IMPORTANT COMPONENTS OF KIDNEY FUNCTION 
 Filteration and preparation of an ultrafilterate. 
 Reabsorption of Glucose, Aminoacids , Electrolytes and Proteins. 
 Homeostasis of Extracellular volume, Acid base status, Blood pressure 
and Electrolytes. 
 Synthesis of Erythropoietin, Glutathione ,Ammonia . 
 Site of Gluconeogenesis. 
 Catabolism of Hormones ,Cytokines. 
 Activation of Vitamin D. 
 Release of Renin. 
 
REQUIREMENTS FOR NORMAL KIDNEY FUNCTION 
The function of kidney depends upon the number and function of 
nephrons present in each kidney. For a nephron to function normally, the 
following conditions must be satisfied
10
. 
1. There must be free flow of blood through the glomerular capillaries. 
      
2. An adequate volume of filterate must be produced which should not 
contain any blood cells or proteins. 
3. The tubules must be able to selectively reabsorb some important 
substances from the filterate and to excrete other substrates into the 
filterate. 
4. The urine formed by the nephron must be able to flow freely from the 
kidney into the bladder and out of the urethra. 
Any derangement of the above function will result in kidney Disease. 
RENAL GLOMERULAR FUNCTION 
About 200L of plasma ultra filterate enter the renal tubular lamina daily by 
glomerular filteration
11
. GFR depends upon the following factors: 
 Balance of pressures across the filteration barrier in the glomerulus 
(difference between the hydrostatic pressure in the glomerular capillaries 
which promote filteration, and the plasma oncotic pressure and 
hydrostatic pressure in Bowman’s space which oppose filteration). 
 Rate of renal plasma flow. 
 Total surface area of the glomerular capillaries. 
GLOMERULAR FILTERATION BARRIER 
An ultra filterate of plasma passes from glomerular capillary blood into 
the space of Bowman’s capsule, through the glomerular filteration barrier12,13. 
The glomerular filteration barrier is made up of three layers. 
1.Capillary endothelium 
      
2.Basement membrane 
3.Podocytes 
Glomerular endothelial cells and podocytes have glycocalyx, a negatively 
charged surface coat. Heparan sulphate, Sialic acid and Sialoproteins are present 
in the glomerular basement membrane. These negative charges impede the 
passage of negatively charged molecules through the glomerular filteration 
barrier by electrostatic repulsion. 
RENAL TUBULAR FUNCTION
14,15,16 
When the plasma filtered into Bowman’s space enters the proximal 
tubule, the process of reabsorption takes place. From the 200L of plasma 
filtered daily, only about 2L of urine is formed. Almost all the reusable nutrients 
and the bulk of electrolytes are reclaimed from the proximal tubules, with fine 
homeostatic adjustments taking place more distally. 
The tubular cells do not actively deal with waste products like Urea and 
Creatinine to any significant degree.Most filtered Urea is passed in urine ,but 
some amount of it diffuses back passively from the collecting ducts with water; 
by contrast , some amount of Creatinine is secreted into the tubular lumen. 
 The tubular cells use Adenosine Tri Phosphate dependent active transport, 
sometimes selectively against physicochemical gradients. Transport of charged 
ions tends to produce an electrochemical gradient that inhibits further transport. 
This is minimized by two processes. 
1. ISOSMOTIC TRANSPORT 
      
 This occurs mainly in the proximal convoluted tubules and reclaims the bulk 
of filtered essential constituents. Active transport of one ion leads to the passive 
movement of another ion of opposite charge in the same direction along the 
electrochemical gradient. For example, isosmotic reabsorption of Na
+
 depends 
on the availability of negatively charged molecules like Cl
-
 .The process is 
isosmotic because the active transport of solute causes movement of equivalent 
amount of ion the same direction. Isosmotic transport also occurs to a lesser 
extent in the distal parts of the nephron. 
2. ION EXCHANGE 
  This occurs mainly in the more distal parts of the nephrons and is important for 
fine adjustment after bulk reabsorption has taken place.Ions of the same charge , 
usually cations are exchanged and neither electrochemical nor osmotic gradients 
are created. For example, Na
+
 may be reabsorbed in exchange for K
+
 and H
+ 
ions. 
 
CHRONIC KIDNEY DISEASE
17 
   Chronic Kidney Disease refers to many clinical abnormalities that 
progressively worsen as kidney function declines. In 2002, The National Kidney 
Foundation Kidney Disease Outcome Quality Initiative (NKF-KDOQI) has 
proposed a definition for CKD to create uniform terminology to improve 
communication among patients, physician and researchers. The definition of 
CKD is either 
      
“ Kidney damage for ≥ 3 months, as defined by structural (or) functional 
abnormalities of the kidney with or without decreased GFR manifested by 
either Pathological abnormalities (or) markers of kidney damage 
including the abnormalities in the composition of the blood or urine or 
abnormalities in Imaging tests”. 
  (Or) 
     “ Glomerular filtration rate < 60ml/min/1.73 m2 for ≥3 months with (or)    
      without kidney damage.” 
    To define CKD , the GFR should be below 60ml/min/1.73m
2
 because it 
represents over a 50% reduction in kidney function as compared to the level for 
young healthy adults. 
   End Stage Renal Disease is defined as either GFR<15ml/min/1.73m
2
 (or) a 
need to start Renal Replacement Therapy either in the form of dialysis (or) renal 
transplantation. Most of the CKD patients will progress to ESRD and they 
require dialysis or kidney transplantation. 
EPIDEMIOLOGY OF CKD IN WORLD
18,19
: 
   CKD is a clinical syndrome that occurs as a gradual decline in renal function 
overtime. As per United States Renal Data System (USRDS) annual data report 
on 2007, one in nine adult has been affected with CKD and 20 million people 
are at risk for CKD. Increasing incidence may be due to aging population, 
Metabolic Syndrome, DM and an increase in the prevalence of Obesity. Of 
about 45% of Type 1 Diabetes mellitus patients develop progressive 
      
deterioration of kidney function within 15-20years after diagnosis. 
Hypertension has profound effects on renal system. Obesity plays an important 
role in the development of kidney disease apart from its role as a risk factor for 
DM and HT. 
GLOBAL PREVALENCE OF CHRONIC KIDNEY DISEASE
20 
 Indicence of CKD is increased two fold in the last 15 years 
globally. 
 In The United States of America , 30million people suffer from 
CKD and 6 lakh people will require Renal Replacement Therapy. 
 Over 1 million people worldwide are alive on dialysis. 
 The reported global annual growth of number of ESRD patients is 
7%
21
. 
 
CURRENT SCENARIO IN INDIA
22,23 
   Approximate prevalence of CKD in Delhi is 7852 per million population and 
the incidence of ESRD is 785 per million (10% of total CKD.) DM has emerged 
as the most frequent cause (30-40%) followed by Hypertension (14-22%). 
 
STAGES OF CHRONIC KIDNEY DISEASE
24 
   The National Kidney Foundation Kidney Disease Outcome Quality Initiative 
(NKF-KDOQI) proposed a widely accepted classification for CKD in which 
CKD is divided into 5 stages. This classification system is based on the level of 
      
estimated Glomerular Filtration Rate (eGFR). The higher  the stage, the lower 
the GFR (or) vice versa. 
   This classification of staging provides the rough estimates of disease 
prevalence of different stages and the characteristics of individuals who are at 
increased risk for developing CKD (or) to allow the development of 
intervention plans for evaluation and management of each stage of CKD. 
 
 
 
 
 
 
 
 
 
 ‘a’ stands for associated risk factors of CKD. ‘b’ stands for demonstrated 
kidney damage (eg) Persistent proteinuria, Abnormal urinary sediment, 
Abnormal Blood and Urine chemistry or Abnormal Imaging studies. 
   GFR can be assessed by either 24 hours Urinary Creatinine Clearance or from 
serum Creatinine by using one of the following formulas
25,26
:   
1. MODIFICATION IN DIET AND RENAL DISEASE(MDRD FORMULA) 
 eGFR = 186 x (Pcr)
-1.154
 x (Age in years) 
-0.203  
STAGES OF CKD GFR ( ml/min per 1.73m
2
) 
0 >90
a
 
1 ≥90b 
2 60-89 
3 30-59 
4 15-29 
5 <15 
      
 Multiply by 0.742 for women. 
 Multiply by 1.21 for Blacks. 
 Pcr – Plasma Creatinine in mg/dl.   
2. COCK CROFT – GAULT EQUATION 
                             (140-Age) x Wt in Kg 
Estimated Creatinine Clearance =________________ 
                              72x Serum Creatinine 
 
 Multiply by 0.85 for females.                                            
 
3. CKD –EPI (EPIDEMIOLOGICAL COLLABORATION ) FORMULA 
  
   eGFR = 141 x min (SCr/k,1)
α
 x max (SCr/k,1) 
-1.209
 x 0.993 
Age
  
 multiply by 1.018 for females 
 multiply by 1.159 for black 
 SCr - serum creatinine (mg/dL) 
 k is 0.7 for females and 0.9 for males 
 α is -0.329 for females and -0.411 for males 
 min indicates the minimum of SCr/k or 1 
 max indicates the maximum of SCr/k or 1 
NATURAL HISTORY OF CKD
27
: 
   Many patients with CKD, stages 3-5 progress relentlessly to ESRD. The 
relationship between the reciprocal of serum Creatinine values (1/Scr) or the 
estimated GFR and time is linear. A significant percentage of patients have 
      
breakpoints in their progression slopes leading to acceleration or slowing down 
of the rate of progression of CKD. They do not follow the predictable linear 
fashion. The breakpoints due to lack of adequate control in systemic Blood 
Pressure or exposure to Nephrotoxins , Non Steroidal Anti-Inflammatory Drugs 
(NSAIDS) or Radio Contrast. The rate of progression of CKD varies depending 
upon the underlying pathology and the individuals. In diabetic individuals the 
rate of progression of CKD is high. It is about 10ml/min/year reduction in GFR. 
In uncontrolled Hypertensive patients it is about 5ml/min/year. If both DM and 
HT are controlled, the reduction in GFR is only 2ml/min/year. 
   In non diabetic individuals, the rate of progression of CKD 2.5 times higher in 
chronic glomerulonephritis than in chronic interstitial nephritis and 1.5 times 
higher than in hypertensive nephrosclerosis. 
 
 
 
 
 
 
 
 
 
 
      
ETIOLOGY OF CKD
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Location of 
Pathology  
(or) Anatomy 
Systemic Diseases 
affecting the kidney 
 
Primary kidney 
Diseases. 
 
 
 
Glomerulus 
Diabetes Mellitus,  
AutoImmune 
Disease,Systemic 
Infection,Drugs , 
Neoplasia. 
Diffuse,focal, 
Crescentric and 
proliferative 
glomerulonephritis, 
focal and segmental 
glomerulo sclerosis, 
minimal change  
Disease. 
 
Tubulo  
Interstitium 
Systemic 
infections, Auto 
immune Diseases, 
Sarcoidosis,  
environmental 
toxins, Urea and 
drugs 
 
Obstruction (or) 
stones and Urinary 
infection. 
 
 
Vascular  
Diseases 
Atherosclerosis, 
Decreased 
perfusion 
 (Liver disease, 
Heart failure, Renal 
artery disease), 
Hypertension, 
Vasculitis, 
Thrombotic 
microangiopathy. 
 
ANCA 
(AntiNeutrophil 
Cytoplasmic 
Antibodies) 
associated 
vasculitis, 
Fibromuscular 
dysplasia. 
 
Congenital 
Alport Syndrome, 
Polycystic Kidney 
Disease, Oxalosis, 
Fabry disease. 
 
Medullary cystic 
disease ,Renal 
dysplasia 
      
PERCENTAGE OF PRIMARY DISEASE CAUSING CKD  
  
 
 
 
 
 
 
 
 
 
 
  The above datas are collected from the CKD registry of 
Indian Society of Nephrology Cumulative Report 2008. 
 
RISK FACTORS OF CKD
29,30 
NON MODIFIABLE RISK FACTORS 
 Old age 
 Race and ethnicity 
 Gender 
 Low birth weight 
 Low socio economic status 
              Diseases Percentage 
Diabetes mellitus 31.2% 
Hypertension 14.1% 
Glomerulo neptritis (GN) 14.4% 
Tubulo Interstitial neptritis 7.0% 
Hereditary (or) cystic diseases 2.1% 
Miscellaneous 15.9% 
Unknown 15.3% 
 Total 100% 
      
MODIFIABLE RISK FACTORS 
 Obesity and Metabolic Syndrome 
 Diabetes Mellitus  
 Hypertension  
 Uric Acid 
 Proteinuria 
MISCELLANEOUS FACTORS 
 Smoking 
 Alcoholism 
 Caffeine 
 Analgesic Abuse 
 Dietary Phytoestrogens 
 Lead and other heavy metal poisoning 
 
CLINICAL PRESENTATION OF CKD
31
: 
STAGE 1: 
   Represents kidney damage when GFR is normal or high. This includes 
patients with proteinuria (or) those with abnormal imaging studies. 
STAGE 2: 
 There is evidence of kidney damage with mild decrease in GFR. 
 In both stages 1 and 2, patients are usually asymptomatic.  
      
 Blood Urea Nitrogen and Serum Creatinine are normal.  
 Acid Base, Fluid and Electrolyte balance are maintained by an adaptive 
increase of function in the remaining nephrons. 
STAGE 3: 
      It includes patients with moderate decline in GFR. This is the stage where 
Serum Creatinine starts to rise. Majority of the patients still remain 
asymptomatic. Nocturia and polyuria are early symptoms that appear at this 
stage. Serum Creatinine and Blood urea nitrogen are increased and the level of 
Erythropoietin, Calcitriol and Parathormone ( PTH) are usually abnormal. 
STAGE 4: 
      They present with severe fall in GFR, and overt Uremic symptoms like loss 
of appetite, nausea, anemia and recurrent infections. They also have 
hypocalcemia, acidosis, hyperphosphatemia and hyperkalemia. 
STAGE 5: 
     When GFR < 15ml/min, there is worsening of all the aforementioned 
symptoms in these patients. At this stage they require Renal Replacement 
Therapy. 
FACTORS AFFECTING INITIATION AND PROGRESSION OF 
CHRONIC KIDNEY DISEASE 
 INITIATION FACTORS 
 GENETIC PREDISPOSITION 
      
CKD often runs within families. Polymorphism of the gene encoding 
RAAS(Renin Angiotensin Aldosterone System), Nitric Oxide Synthase, 
Kallikrein, IL-1, TNFα , Platelet Derived Growth Factor (PDGF), Transforming 
Growth Factor-β (TGF-β1), Plasminogen Activator Inhibitor-1(PAI-1), 
Complement factors and Immunoglobulins are the possible links of CKD. 
 RACIAL FACTORS 
Racial predisposition attributed to a number of factors such as DM, HT 
Susceptibility and also genetic susceptibility . Social deprivation or low social 
economic status are linked to the higher prevalence of CKD in the developing 
countries. 
 MATERNAL AND FETAL FACTORS 
Maternal malnutrition during pregnancy and resulting fetal malnutrition 
may contribute to the development of HT, Metabolic Syndrome, DM, CKD in 
adult life. Reduction in the number of nephron at birth (oligonephronia) and 
their ability to handle increased solute and salt load leads to glomerulosclerosis 
and CKD. 
 OTHER FACTORS 
Males and elderly people are more prone to develop CKD. 
 INITIATION MARKERS 
 Hypertension – Elevated BP in both men and women is a risk factor for 
ESRD. 
 Diabetes Mellitus 
      
 Hyperlipidemia – Increased Triglycerides(TGL) is associated with CKD. 
 Obesity  
 Smoking is associated with increased risk for proteinuria in men. 
 
PROGRESSION FACTORS 
The progression of CKD is variable and associated with the variety of 
risk factors and markers: 
AGE 
 Rate of progression of CKD is influenced by age. Elderly Patients 
affected by GN having a faster rate of GFR decline than young people except 
Type1 DM, in which young individuals having a faster rate of GFR decline. 
GENDER: 
 Male gender was often associated with more rapid GFR decline and rapid 
progression. 
RACE: 
 In United Kingdom , Indo-Asian patients with Diabetic Nephropathy may 
have a faster rate of decline of GFR than Caucasians. 
GENETICS:  
 Patients with Polycystic Kidney Disease (PKD) carrying the genotype 
PKD1, have a worse prognosis than others. Angiotensin Converting Enzyme 
(ACE) gene polymorphism, either deletion (or) Insertion also involved in 
linking between susceptibility and progression of CKD. 
      
LOSS OF RENAL MASS: 
 The threshold for nature progression in terms of GFR loss appears to be 
crossed when loss of nephron function exceeds 50%. 
MODIFIABLE RISK FACTORS AND MARKERS.  
HYPERTENSION 
Transmission of systemic hypertension into glomerular capillaries and the 
subsequent development of glomerular hypertension contributes to the initiation 
and progression of glomerular sclerosis. 
 
 
PROTEINURIA 
Degree of proteinuria is associated with the rate of progression of CKD. 
Heavy proteinuria is associated with faster rate of progression. Non selective 
proteinuria is mainly responsible for the natural progression of CKD whereas 
the highly selective proteinuria (eg) Albuminuria can persist for more than 10 
years in the nephrotic range without causing structural damage to the kidney. 
METABOLIC MARKERS AND FACTORS 
 GLYCEMIC STATUS 
Degree of glycemia is associated with the rate of progression of 
CKD. Higher the degree of glycemia , faster the rate of progression of 
CKD. 
 LIPIDS 
      
Dyslipidemia is the contributory factor for glomerulosclerosis and 
tubulointerstitial fibrosis. 
 OBESITY 
Excess body weight and high body mass index have been linked to 
a rapid progression of CKD. 
 URIC ACID 
Hyperuricemia may cause hypertension and renal injury through 
stimulation of Renin Angiotensin System. 
MISCELLANEOUS FACTORS 
 SMOKING 
Cigarette smoking increases systemic blood pressure and alters the 
renal hemodynamics leading to rapid progression of CKD. 
 ALCOHOL AND RECREATIONAL DRUGS 
Alcohol consumption increases the rate of progression of CKD 
through the effect of hypertension. The use of recreational drugs such as 
Opiates is associated with the progression of CKD. 
 CAFFEINE 
Excessive exposure to Caffeine leads to progression of renal 
scarring. 
 ANALGESICS AND NSAIDS  
      
Ingestion of Phenacetin , Paracetamol, Aspirin and NSAIDS are 
associated with the increased risk of ESRD. 
 LEAD EXPOSURE: 
Chronic Lead exposure is implicated in the development of ESRD. 
 
PATHOPHYSIOLOGY
28 
 
The pathophysiology of CKD is a complex process and is dependent on the 
primary cause. After an acute or chronic insult, many common pathways are 
activated to perpetuate glomerular and tubulointestinal injury. There are two 
types of injuries. 
 
 
 
 
 
 
 
 
 
 
      
FIGURE.1 
PATHOGENESIS OF CHRONIC KIDNEY  
DISEASE 
 
 
 
 
 
 
 
 
 
      
1. Hemodynamic injury 
2. Non-hemodynamic injury 
HEMODYNAMIC INJURY 
This process occurs at a linear rate in proportion to the greater reduction 
in kidney mass resulting in an increase in renal plasma flow and hyperfilteration 
of the remaining nephrons. Systemic hypertension and RAAS mediated 
glomerular hypertension cause progressive glomerular damage and proteinuria, 
resulting in decreased afferent arteriolar tone than the efferent tone. This net 
efferent vasoconstriction increases intraglomerular pressure and filteration 
pressure further more, perpetuating hyperfilteration injury. 
With loss of functioning nephrons, Renin is released from the Juxta 
Glomerular Apparatus due to decreased perfusion pressure and low Sodium 
delivery to the Macula Densa. Renin converts Angiotensinogen to Angiotensin 
I. This Angiotensin I is converted into angiotensin II with the help of 
Angiotensin Converting Enzyme. Angiotensin II is the main perpetrator of 
glomerular hemodynamic maladaptation. 
Angiotensin II is the potent vasoconstrictor in the post glomerular 
arterioles.It also increases proximal tubular Sodium reabsorption directly and 
distal tubular Sodium reabsorption indirectly through Aldosterone. Lastly, it 
also stimulates posterior pituitary to release AntiDiuretic Hormone. 
 All these mechanisms are an integral component of autoregulation 
helping to maintain GFR when perfusion is decreased. The increase in 
      
glomerular hypertension increases the filteration fraction and radius of the pores 
in the glomerular basement membrane resulting in clinical proteinuria and 
glomerular destruction. 
 
NON-HEMODYNAMIC INJURY 
Non hemodynamic maladaptive pathways lead to inflammation and 
fibrosis of kidney. Angiotensin II level is increased in virtually every 
compartment of the kidney such as mesangial cell, endothelial cells, podocytes, 
the urinary space (Bowman’s capsule) and the tubulointerstitium. 
Increased Angiotensin II which upregulates several growth factors and 
their receptors  like Connective Tissue Growth Factor, Epidermal Growth 
Factor, Insulin Like Growth Factor-1, PDGF ,Vascular Endothelial Growth 
Factor(VEGF), Transforming Growth Factor-β and Monocyte Chemotactic 
Protein -1. The activation of these factors leads to over production of 
extracellular matrix by upregulating other factors such as Type1 procollagen, 
PAI-1 and Fibronectin. In addition to that , excess adhesion molecules like 
Integrins or Vascular Cell Adhesion Molecule 1 allow the increased 
extracellular matrix and hypercellularity to accumulate resulting in cell 
proliferation, extra cellular matrix accumulation, adhesion of these cells and 
functional changes ultimately resulting in fibrosis. 
 
      
Inflammation is the key factor in the progression of all types of kidney 
disease and it is mediated partly by RAAS. Angiotensin II recruits macrophages 
and T cells by stimulating Endothelin -1 and increased the production of 
Nuclear Factor k light chain enhancer of activated B cells. These molecules will 
release cytokines creating more inflammation. TGF-β is also responsible for 
cellular recruitment. Free radical oxygen species creates an additional injury 
which enables further inflammation and fibrosis.  
Through primary stimulation of the RAAS, a cascade of events beginning 
with inflammation occurs which is perpetuated by accumulation of cells and 
matrix, and is exacerbated by adhesion of these cells and matrix resulting in 
glomerulosclerosis and tubulointerstitial necrosis. This creates a progressive 
course of CKD, proteinuria, decline in GFR and a vicious cycle of continuous 
RAAS activation.    
Figure.1. shows the pathophysiology of progressive chronic kidney 
disease.It represents both hemodynamic and non hemodynamic mediated injury 
to the kidney to the development of CKD.          
                                                                                                           
MECHANISMS OF PROGRESSION OF CHRONIC KIDNEY DISEASE 
The progression of CKD is associated with the progressive sclerosis of 
glomeruli irrespective of the nature of underlying nephropathy. Both intra and 
extra glomerular cells contribute to the initiation and progression of glomerulo 
sclerosis. 
      
INTRA GLOMERULAR CELLS 
ROLE OF GLOMERULAR ENDOTHELIAL CELLS: 
Glomerular endothelium performs an important role in preserving the 
integrity of vascular beds of glomeruli. They are the first exposed to the damage 
caused by hemodynamic injury, immunologic and metabolic injury. This 
endothelial injury is associated with the loss of their anticoagulant and anti 
inflammatory characteristics and gain of procoagulant and inflammatory 
properties leading to attraction and activation of platelets and microthrombus 
formation. 
It is further associated with the initiation of glomerular micro 
inflammation with the attraction, adhesion and infilteration of glomerular tufts 
by monocytes. Then platelets and monocytes interact with mesangial cells 
resulting in production of extra cellular matrix (ECM). 
 ROLE OF MESANGIUM 
After endothelial injury, the infiltrating monocytes interact with the 
mesangial cells and stimulate them either through direct cell to cell interaction 
or through release of mitogens like PDGF. The transcription factor kappa B 
(NF-κB) and a variety of kinases [ Mitogen Activated Protein kinase ( MAPK) 
and Jun N-terminal kinase or stress activated protein kinase] are involved in the 
proliferation of mesangial cells. 
Activated mesangial cells have the capacity to revert to a myofibroblasts 
expressing markers such as α smooth muscle Actin, under the control of 
      
Fibrogenic Growth Factor like TGF-β1 and synthesizes interstitial Type III 
collagen which is not a normal component of glomerular extra cellular matrix. 
Resolution of glomerular and mesangial sclerosis depends upon the balance 
between the increased extra cellular matrix and its breakdown by 
metalloproteinases and glomerular collagenases. 
 
ROLE OF GLOMERULAR EPITHELIAL CELLS 
The relative inability of podocytes to replicate with respect to injury may 
cause their stretching along the glomerular basement membrance. This will 
expose the areas of denuded glomerular basement membrane. Attraction and 
interaction of denuded glomerular basement membrance with the parietal 
epithelial cells forms capsular adhesions and subsequent segmental 
glomerulosclerosis. Tuft-to-capsule adhesions allow the influx of 
periglomerular fibroblasts into the glomerualr tuft causing glomerulosclerosis.  
EXTRA GLOMERULAR CELLS: 
PLATELETS  
The stimulation of the coagulation cascade by the activation of platelets 
and their release products will activate the mesangial cell and promote its 
sclerosis. 
 Thrombin stimulates TGF-β1, resulting in progression of mesangial  extra 
cellular matrix production . 
      
 Upregulation of plasminogen activator inhibitor -1 within the damaged 
glomeruli may lead to extra cellular matrix accumulation and glomerulo 
sclerosis because of its inhibition of proteolytic enzyme plasmin. 
  Degree of glomerulosclerosis depends upon the balance between 
thrombotic- antiproteolytic and anticoagulant- proteolytic activities. 
 
LYMPHOCYTES, MONOCYTE AND MACROPHAGES 
The release of Cytokines, Growth Factors and Procoagulant factors by 
lymphocytes as well as monocytes and macrophages is likely to contribute to 
the pathogenesis and progression of glomerulosclerosis. 
BONE MARROW – DERIVED CELLS 
Hematopoietic stem cells are involved in the normal glomerular cell 
turnover and response of glomeruli to injury. 
 
TUBULO INTERSTITIAL SCARRING: 
Tubulo interstitial fibrosis is developed in three stages. 
1. Inflammation of tubulointerstitium. 
2. Proliferation of interstitial fibroblasts. 
3. Excessive deposition of interstitial extracellular matrix  
Renal tubular cells play an important role in the pathogenesis of 
tubulointerstitial fibrosis. Injured tubular cells act as antigen presenting cells 
      
expresses cell adhesion molecules and releases inflammatory mediators and 
growth factors resulting in increased synthesis of ECM. 
Loss of complementary proteins in the glomerular proteinuria may 
damage the tubular cells. Tubular cells may also be stimulated by the spillover 
of hormones such as Angiotensin II, Growth Factors and Cytokines from 
injured glomeruli. 
Activation of tubular cells and their release of chemotactic factors can 
attract inflammatory cells including monocytes to the tubules and renal 
interstitium with subsequent activation of renal fibroblasts. 
Activated renal fibnoblasts acquire myofibroblast characteristics [eg. 
express α – smooth muscle Actin and synthesize interstitial Type I and III 
collagen] proliferate and invade the periglomorular and peritubular spaces. The 
resolution of deposited extracellular matrix depends on activation of Matrix 
Metalloproteinases and Plasmin. Inhibition of these two protolytic enzymes 
results in tubulo interstitial scarring. 
Tubular cells contribute to fibrogenesis through their transformation into 
a myofibroblastic phenotype is called epithelial mesenchymal transformation. 
This is a form of reverse embryogenesis because proximal tubules are derived 
ontogenetically from the metanephric mesenchyme. 
VASCULAR SCLEROSIS 
This is an integral feature of the renal scarring process. Renal arteriolar 
hyalinosis is associated with progression of CKD. This may be present at the 
      
early stage of CKD, even in the absence of severe hypertension. Hyalinosis of 
afferent arterioles may be implicated in the pathogenesis of glomerulosclerosis. 
Hyalinosis of the post glomerular arterioles may exacerbate interstitial ischemia 
and fibrosis. Ischemia and the ensuing hypoxia stimulate tubular cells and 
kidney fibroblasts to produce extra cellular matrix components and reduce their 
collagenolytic activity. 
COMPLICATIONS OF CKD 
 ANAEMIA32 
     Several factors implicated in the development of anaemia. 
They are  
 Erythropoietin deficiency. 
  Retention of Bone marrow toxins . 
 Bone marrow fibrosis secondary to hyperparathyroidism. 
 Haematinic deficiency – Iron, Vitamin B12, Folate. 
 Increased red cell destruction. 
 Abnormal red cell membranes causing increased osmotic fragility. 
 Increased blood loss – occult gastro intestinal bleeding, blood loss during 
haemodialysis or because of platelet dysfunction. 
 Drugs like ACE inhibitors may cause anaemia in CKD by interfering 
with the control of endogenous Erythropoietin release. 
 
 
      
  RENAL OSTEODYSTROPHY 
 Decreased renal production of the 1α hydroxylase enzyme results in 
reduced conversion of 25-OH cholecalciferol to 1,25 dihydroxy 
cholecalciferol. 
 Reduced activation of vitamin D receptors in the parathyroid gland leads 
to increased release of PTH. 
 Calcium sensing receptors expressed in the parathyroid glands react 
rapidly to acute changes in serum Calcium concentrations and a low 
Calcium also leads to increased release of PTH. 
 1,25 dihydroxy cholecalciferol deficiency also results in gut Calcium 
malabsorption. 
 Phosphate retention owing to reduced excretion by the kidneys lowers 
ionised Calcium, results in an increase in PTH synthesis and release. 
 PTH promotes reabsorption of Calcium from bone and increased 
proximal renal tubular reabsorption of Calcium and this opposes the 
tendency to develop hypocalcemia induced by 1,25 dihydroxy 
cholecalciferol deficiency and phosphate retention. 
 
DEFINITION OF CKD-MBD
33,34 
A systemic disorder of mineral and bone metabolism due to CKD is 
manifested by either one or a combination of the following: 
      
 Abnormalities of Calcium, Phosphorous, Parathormone and vitamin D 
metabolism.  
 Abnormalities in bone turn over, mineralization volume, linear growth or 
strength. 
 Vascular or other soft tissue calcification. 
 
 FLUID, ELECTROLYTE AND ACID-BASE DISORDERS  
 SODIUM AND WATER HOMEOSTASIS 
 In most patients with stable CKD, the total-body content of Sodium and 
water is modestly increased. 
 Normal renal function guarantees that the tubular reabsorption of 
filtered Sodium and water is adjusted so that urinary excretion matches 
net intake of Sodium and water.  
 Many forms of renal disease (e.g., Glomerulonephritis) disrupt this 
glomerulotubular balance such that dietary intake of Sodium exceeds its 
urinary excretion, leading to sodium retention and attendant 
extracellular fluid volume expansion.  
 This expansion may contribute to hypertension, which itself can 
accelerate the nephron injury.  
      
 As long as water intake does not exceed the capacity for water 
clearance, the extracellular fluid volume expansion will be isotonic and 
the patient will have a normal plasma Sodium concentration and 
effective osmolality. 
 Hyponatremia is not commonly seen in CKD patients.  
 POTASSIUM HOMEOSTASIS 
 In CKD, the decline in GFR is not necessarily accompanied by a 
parallel decline in urinary Potassium excretion, which is predominantly 
mediated by Aldosterone-dependent secretory events in the distal 
nephron segments. 
 Another defense against Potassium retention in these patients is 
augmented Potassium excretion in the gastro intestinal tract.  
 Against defense mechanisms s hyperkalemia may be precipitated by 
increased dietary Potassium intake, protein catabolism, hemolysis, 
hemorrhage, transfusion of stored red blood cells, and metabolic 
acidosis.  
 Hypokalemia is not common in CKD and usually reflects markedly 
reduced dietary potassium intake, especially in association with 
excessive diuretic therapy or concurrent gastro intestinal losses. 
  
      
 METABOLIC ACIDOSIS 
 Metabolic acidosis is a common disturbance in advanced CKD. 
 This is a non-anion-gap metabolic acidosis.  
 With worsening renal function, the total urinary net daily acid excretion is 
usually limited to 30–40 mmol, and the anions of retained organic acids 
can then lead to an anion-gap metabolic acidosis.  
 The non-anion-gap metabolic acidosis that can be seen in earlier stages of 
CKD may be complicated by the addition of an anion-gap metabolic 
acidosis as CKD progresses.  
 In most patients, the metabolic acidosis is mild; the pH is rarely <7.35 . 
 SKIN DISEASE 
Pruritus is common in severe CKD and is due to retention of nitrogenous 
waste products of protein catabolism. It improves following dialysis. 
 OTHER CAUSES OF PRURITUS IN CKD 
 Hypercalcemia 
 Hyperphosphataemia 
 Elevated calcium x phosphate product 
 Hyperparathyroidism 
 Iron deficiency 
 
 
      
 NEPHROGENIC SYSTEMIC FIBROSIS 
It is seen only in patients with moderate to severe CKD particularly in 
patients on dialysis . Skin is predominantly involved. 
 GASTROINTESTINAL COMPLICATIONS 
 Decreased gastric emptying 
 Increased risk of reflux oesophagitis 
 Peptic ulceration 
 Acute pancreatitis 
 Constipation 
 Elevated serum amylase of upto three times normal, due to retention of 
high  molecular weight forms of amylase in the body. 
 METABOLIC ABNORMALITIES 
 Gout – Uric acid retention is a common feature of CKD. 
 Insulin- Insulin is catabolized by kidney and to some extent it is 
excreted by kidneys. End organ resistance to insulin is a feature of 
advanced CKD resulting in modestly impaired glucose tolerance. 
 ABNORMALITIES OF LIPID METABOLISM35,36 
Progressive deterioration of renal function results in altered composition of 
blood lipids which in turn predisposes to the development of cardio vascular 
disease. Renal dyslipidemia is characterized by the following features: 
      
 Hepatic apo AI synthesis is decreased and Lecithin cholesterol acyl 
transferase activity is reduced. This leads to decreased HDL-C levels. 
 Increased synthesis of apo C III, a competitive inhibitor of Lipoprotein 
Lipase leads to elevated levels of VLDL-C and Chylomicrons, which 
results in hypertriglyceridemia. Further, uremic toxins and secondary 
hyperparathyroidism reduces the levels of lipoprotein lipase which results 
in impaired catabolism of Triglyceride rich lipoproteins. Insulin resistance 
associated with CKD also increases the VLDL-C levels. 
 Total and LDL- Cholesterol levels are usually normal but may be low in 
patients with concomitant inflammation and malnutrition. There is 
characteristic accumulation of small dense atherogenic LDL-C. 
 As GFR declines, the levels of high molecular weight isoforms of 
Lipoprotein (a) increase which is associated the increased cardiovascular 
risk. 
 The changes in lipoprotein composition and structure in CKD stimulate 
and amplify the already existing inflammatory mechanisms which in turn 
results in endothelial dysfunction and atherosclerotic progression. 
 ENDOCRINE ABNORMALITIES 
 Hyperprolactinaemia 
 Increased Luteinizing hormone (LH) levels in both sexes and abnormal 
pulsality of LH release. 
      
 Decreased serum Testosterone level, so erectile dysfunction and 
decreased spermatogenesis are common. 
 Absence of normal cyclical changes in the female sex hormones resulting 
in oligo-menorrhoea or amenorrhoea. 
 Abnormalities in Growth Hormone secretion and action resulting in 
impaired growth in uraemic children. 
 Abnormal Thyroid hormone levels, partly because of altered protein 
binding. 
 MUSCLE DYSFUNCTION 
    Uremia interferes with muscle energy metabolism. 
 NERVOUS SYSTEM  
Severe uremia causes an depressed cerebral function and decreased 
seizure threshold, asterixis , tremor and myoclonus.  
 
 CARDIO VASCULAR DISEASE  
    The overall mortality rate from cardiovascular disease in CKD patients 
has been found to be about 30 times greater than that of general population
37
. 
Patients with all stages of CKD are considered as the highest risk group for 
CVD. CKD is therefore considered as a “cardiovascular risk equivalent. 
Cardiovascular disease is characterized by left ventricular hypertrophy 
which results largely due to expansion of extracellular volume, anemia and 
      
hypertension. Left ventricular remodelling and fibrosis may accompany left 
ventricular hypertrophy which ultimately results in severe complications
38
. 
Cardiovascular complications associated with CKD include Myocardial 
infarction, Angina pectoris, Arrhythmias, Cardiac failure, Peripheral Vascular 
Disease, Stroke and Sudden death. The risk increases from early stages to 
advanced stages of CKD. 
CARDIOVASCULAR RISK FACTORS IN CKD
39,40 
TRADITIONAL RISK FACTORS 
 Age 
  Gender  
 Diabetes Mellitus 
  Hypertension  
 Smoking 
NON-TRADITIONAL RISK FACTORS 
 Inflammation 
 Oxidative stress 
 Endothelial dysfunction 
 Anaemia 
 Hyperphosphatemia 
 Secondary hyperparathyroidism 
      
 Vascular calcification 
 Advanced glycation end products 
 Hyper homocystinemia 
 INFLAMMATION41,42,43  
Most CKD patients are in a state of chronic inflammation. Various factors 
may be associated with a sustained inflammatory response in CKD which 
include 
 Genetic background 
 Persistence of inflammatory conditions 
 Exogenous (bacteria, viruses) 
 Endogenous (Reactive oxygen species , glycated and 
oxidized  adducts , Renin Angiotensin Activating System) 
 Failure of clearance of inflammatory mediators (cytokines and other 
mediators and glycated, oxidized adducts) 
 Dysmetabolic states 
 Dyslipidemia 
 Central obesity 
 Insulin resistance 
The most commonly used biomarker of inflammation is C-reactive 
protein (CRP) which is one of the member of Pentraxin family and the 
prototypic acute phase reactant. Other acute phase reactants include Serum 
      
Amyloid A, Ferritin and Fibrinogen.These proteins are the forward or positive 
acute phase reactants whose serum levels increase during inflammation. The 
negative phase reactants include Albumin and Prealbumin and the level of these 
proteins fall during inflammation. 
CRP, Interleukin-6 and Fibrinogen are the independent predictors of 
mortality in CKD patients. These markers have been attributed to their pro-
atherogenic properties such as endothelial dysfunction, promotion of vascular 
calcification and oxidative stress. 
 
 
 NUTRITIONAL ABNORMALITIES 
 Protein-energy malnutrition, a consequence of low protein and caloric 
intake, is common in advanced CKD and is often an indication for 
initiation of Renal Replacement Therapy. 
 These patients are resistant to the anabolic actions of insulin and other 
hormones and growth factors. Metabolic acidosis and the activation of 
inflammatory cytokines can promote protein catabolism.  
 
 
      
 
 
 
 
VISFATIN 
DISCOVERY
44,45,46,47 
 
 
 In 1960s, researchers found a protein with enzymatic activity in liver 
extracts which was named as Nicotinamide Phosphoribosyl Transferase 
(Nampt). In 1994, an another group of researchers identified the gene with same 
action in cDNA library from human peripheral blood lymphocytes and named it 
as Pre-B- cell colony Enhancing Factor-1 (PBEF-1). 
The protein which is secreted by peripheral blood lymphocytes is also 
found to be secreted by visceral adipose tissue. Since the primary source of 
protein is visceral adipose tissue ,it is renamed as visfatin(visceral fat derived 
adipokine) by Fukuhara and colleague in 2005
48
.   
MOLECULAR GENETICS 
 
Visfatin is a 52 KDa protein. The sequence of visfatin is highly conserved 
among vertebrates, invertebrates, bacteria and bacteriophages
49,50
. The gene for 
Visfatin is locacted on chromosome 7 between 7q 22.1 and 7q31.33. This gene 
      
has a pseudogene on chromosome 10. It is composed of 11 exons and 10 introns. 
It is encoding 491 Amino acid residues. It spans 34.7 kb length of human 
genomic DNA
51,52
. Three mRNA transcripts exist at sizes of 2.0, 2.4 and 4.0kb. 
Among these three, 2.4kb is the predominant one. The variations in size may be 
due to alterations in either exon splicing or sites of polyadenylation. The 
Visfatin gene has 2 distinct promoters and so the gene and gene products may 
be differentially expressed in different tissues.  
SECRETION AND  EXPRESSION
53,54 
 
Visfatin is ubiquitously expressed and associated with a variety of 
functions in different cell types. Apart from leucocytes and adipocytes, Visfatin 
is also expressed in hepatocytes, skeletal muscle, heart, brain, placenta, kidney, 
lung, pancreas and bone marrow. In addition to tissue localization, It is also 
identified in the plasma of humans. The exact mechanism of its secretion into 
the plasma is unknown, because it lacks a signal peptide. It occurs through a 
non classical secretory pathway. 
In mammals, there are two forms of Visfatin have been identified. 
1. Intracellular Visfatin / Nampt: 
Involved in the regulation of cellular metabolism in response to 
nutrient availability, cell maturation and survival. 
2. Extracellular Visfatin/Nampt: 
Secreted by different cell types acting as a proinflammatory molecule.  
      
Visfatin secretion is a highly regulated process. Its secretion is cell type 
dependent because brown adipose tissues secrete more Visfatin than white 
adipose tissues. The plasma level of Visfatin correlates with the volume of 
visceral fat but not with the quantity of subcutaneous fat
55
. Cellular distribution 
of Visfatin varies with the growth phase of the cell, being predominantly 
nuclear in non proliferating cells and cytoplasmic in proliferating cells
56
. 
STRUCTRUE
57,58,59 
 The crystal structure of Visfatin with regard to its enzymatic function is a 
homodimeric protein. It has two active sites at the interface of the dimeric 
protein. So homodimerization is essential for the catalytic activity of the 
enzyme. The extensive dimeric interface with a total surface area of 8077A
0 2 
is 
formed by 10 segments from each unit. 
 Of about 89 polar and hydrophobic residues are distributed along the 
interface and 42 hydrogen bonds are involved in the intra molecular 
interactions. 
 Each monomer is composed of 491 residues that form 13 helices and 19 
strands consisting of 2 structural domains. The first structural domain is 
organized into 7 stranded anti parallel β sheets, 2 anti parallel β strands and one 
α helix. The second domain is arranged into alternative folding of the classical 
(β/α)s barrel. Alignment of 13 residues in the active site of Visfatin / Nampt is 
highly conserved. 
 Figure.2. represents the crystal structure of Visfatin. 
      
 
 
  
FIGURE.2 
CRYSTAL STRUCTURE OF VISFATIN 
 
SCHEMATIC RIBBON DIAGRAM OF VISFATIN SHOWS 
THE THE PRESENCE OF TWO MONOMERS, COMPRISING 
OF 491 AMINO ACIDS. α  HELICES   ARE REPRESENTED  
BY GREEN CYLINDERS. β SHEETS ARE REPRESENTED BY  
ORANGE ARROWS. 
 
      
 
BIOLOGICAL FUNCTIONS OF VISFATIN. 
 
Numerous biological functions have been attributed to Visfatin. Most 
important functions are 
 
1. Visfatin catalyzes the first step in synthesis of NAD –Enzymatic 
action of Visfatin. 
2. Pro inflammatory cytokine – paracrine effect of Visfatin. 
3. Insulin mimetic action – Endocrine effect of Visfatin. 
4. Intracellular Visfatin enhances the insulin sensitivity 
in liver – Autocrine effect of Visfatin. 
The immune, inflammatory and metabolic responses of Visfatin depends 
on both extracellular (cytokine like) and intra cellular (enzymatic) isoforms
60
. 
Visfatin is upregulated by hypoxia, inflammation and hyperglycemia. Visfatin 
is downregulated by Insulin, Somatostatin and Statins. Visfatin is an endocrine, 
autocrine as well as paracrine peptide with many functions
61
.  
ACTS AS AN ENZYME 
Visfatin participates in  Nicotinamide metabolism by acting as an enzyme 
named Nampt which belongs to the family of Pentosyltransferases and 
catalyzes the following chemical reaction: 
      
 
Nampt is the rate limiting enzyme, involved in both extra and 
intracellular formation of Nicotinamide Mononucloeotide(NMN). An another 
enzyme Nicotinamide mononucloeotide adenylyl transferase (Nmnat) converts 
NMN to NAD thus replenishing the NAD pool within the cell. 
 
NAD
+ 
is an essential cofactor of fundamental intracellular processes such as  
 Transfer of electrons during redox reactions, DNA repair mechanisms, 
transcriptional regulation. 
 To modulate the activity of key regulators of cellular longevity. 
 To serve as a substrate for the generation of other biologically important 
molecules.  
 Regulation of intracellular signaling. 
 Involved in energetic metabolism by influencing the activity of 
NAD/NADH dependent enzymes. 
 
      
NAD
+
 acts as a cofactor a family of Class 3- NAD
+
-dependent Histone 
deacetylases known as SIRTs (silent information regulator 2) or Sirtuins. It 
binds to NAD
+
 and a target protein that contains an acetylated lysine. It 
catalyzes the formation of acetylated ADP-ribose by deacetylation of the lysine 
residue of the target protein. These sirtuins are essential for certain cell survival 
reactions
62
. 
 
  Sirtuins have been implicated in influencing aging and regulating 
transcription,  apoptosis and stress resistance. Nampt indirectly helps in the 
longevity of the cells life span. Nampt extends the lifespan and promotes the 
maturation of human smooth muscle cells by activating SIRT1. All these 
reactions will cleave NAD and utilize it. So a salvage pathway is essential to 
replesnish the cellular NAD pool
63
. 
ROLE AS A PRO INFLAMMATORY CYTOKINE
64
                   
Visfatin increases the effect of IL-7 and stemcell factor on pre B cell 
colony formation so it is named as PBEF-1. It also increases the expression of 
inflammatory cytokines such as IL-6, IL-1β and TNF α.  
 
 
 
 
      
FIGURE.3 
INSULINO-MIMETIC ACTION OF 
VISFATIN 
 
  
 
 
 
 
      
ACTS AS AN ANTI APOPTOPIC
65,66 
 
Apoptosis is programmed cell death. Removal of intact neutrophils is 
necessary to prevent chronicity of the disease, because it leads to recognition of 
intact senescent neutrophils that have not necessarily disgorged their granule 
contents. Visfatin is also secreted by neutrophils in response to inflammatory 
stimuli and acts as an inhibitor of apoptosis resulting from a variety of 
inflammatory stimuli.  
 
ACTS AS AN INSULIN – MIMETIC HORMONE 
 
Visfatin binds to Insulin receptor at a site different from that of Insulin. 
After binding with insulin receptor, it causes tyrosine phosphorylation as well as 
phosphorylation of Insulin Receptor Substance (IRS) -1 and 2 and down stream 
signaling kinases (like Protein Kinase B and Mitogen Activated Protein Kinase) 
leading to enhanced glucose uptake. The affinity of Visfatin and Insulin for 
insulin receptors are same but the circulating concentration of Visfatin is 10 
times lower than that of Insulin. Acting as Insulin mimetic hormone, Visfatin 
increases glucose transport and lipogenesis by adipose tissues and myocytes and 
decreases glucose production by hepatocytes.Figure.3. shows the Insulino-
mimetic action of Visfatin. 
 
 
      
FIGURE.4 
ACTIONS OF VISFATIN IN CARDIO VASCULAR  
SYSTEM 
 
 
 
 
 
 
 
 
 
 
      
ROLE OF VISFATIN IN CKD
67,68,69
,
70 
 
There is impaired renal filteration function in CKD leading to 
accumulation of uremic toxins within the body.There are three groups of uremic 
toxins such as water soluble, protein bound and middle molecule uraemic 
retention solutes.  
Visfatin is a middle molecule uraemic retention solute of wt 52 KDa , 
synthesizes NAD ,which is important for vascular smooth muscle maturation 
suggesting its potential role in vascular pathology. Proliferation of vascular 
smooth muscle cell is a hallmark of development of Atherosclerosis . Visfatin 
stimulates the Vascular Endothelial Growth Factor (VEGF) synthesis and 
secretion and also enhances the expression of VEGF receptor 2 that promotes 
endothelial proliferation.  
Visfatin  also upregulates other proangiogenic soluble factors such as 
Fibroblast Growth Factor 2, MCP -1 (Monocyte Chemotactic Protein-1) and IL-
6 in endothelial cells.Figure.4. shows the various actions of Visfatin in 
Cardiovascular system to cause atherosclerosis.It acts through cell proliferation  
of endothelial cell and vascular smooth muscle cell resulting in angiogenesis 
and atherosclerosis.  
Visfatin activates human leukocyte expression of Interleukin- 1β, Tumor 
Necrosis Factor-α, Interleukin-6 as well as Matrix Metalloproteinase-9 activity 
suggesting that there is a potential link between Visfatin and Inflammation. 
      
Inflammation is an ubiquitous feature of CKD associated with an adverse 
outcome of CVD. It is therefore reasonable to propose that Visfatin is 
contributing to the pathogenesis of Atherosclerosis and Cardiovascular disease 
in CKD patients as it acts as a pro- inflammatory cytokine and plays a role in 
chronic inflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
AIMS AND OBJECTIVES 
AIM: 
     To estimate the levels of serum Visfatin in patients with CKD and to 
compare them with healthy controls. 
 
OBJECTIVES: 
1. To study the relationship of serum Visfatin with the inflammatory 
biomarker hsCRP. 
2. To evaluate the association of serum Visfatin with Creatinine 
clearance. 
3. To find out the correlation of serum Visfatin with lipid profile. 
 
 
 
 
 
 
 
 
 
 
 
      
MATERIALS AND METHODS 
The study was conducted at Thanjavur Medical College Hospital, 
Thanjavur after getting approval from the ethical committee. 
50 patients of known CKD (25 males and 25 females) were selected as 
cases from the outpatients and wards of the Department of Nephrology. 50 age 
and gender matched healthy individuals were selected as controls. 
INCLUSION CRITERIA 
 Patients with established diagnosis of CKD. 
 Age > 18 years. 
EXCLUSION CRITERIA 
 Acute/chronic inflammatory diseases( sepsis, infection, malignancy 
and liver disease). 
 Previous history of Coronary Artery Bypass Graft surgery. 
 Patients on lipid lowering drugs. 
 Acute kidney injury. 
 Patients on immuno therapy. 
 Previous history of cerebrovascular diseases. 
 Patients who underwent renal transplantation. 
 Nephrotic syndrome. 
 
      
Informed consent was obtained from all subjects prior to the study. Under 
aseptic precautions, 5ml of venous blood sample was collected after an 
overnight fasting of 12 hours from  all subjects. After retraction of the clot, 
samples were centrifuged at 2000rpm for 15 minutes for separation of serum. 
 
An aliquot of the serum was taken for the estimation of Visfatin and 
stored at -20°C in the deep freezer. The remaining serum was used for the 
estimation of Glucose, Urea, Creatinine, hsCRP, Total cholesterol (TC), 
Triglycerides (TGL) and High Density Lipoprotein Cholesterol (HDL-C). 
 
ANALYSIS OF BLOOD SAMPLES 
 
The serum collected above was used for the estimation of the following 
parameters. 
 
A. ESTIMATED PARAMETERS 
1. Serum Visfatin            Enzyme Immuno Assay. 
2. Serum hsCRP             Turbidimetric Immunoassay. 
3. Blood Urea               Urease –Glutamate Dehydrogenase (GLDH) 
                             Method. 
4. S.Creatinine           Modified Jaffe’s method. 
5. Total  Cholesterol        Cholesterol Oxidase- PAP method 
6. Triglycerides               Glycerol Phosphate Oxidase –PAP method 
      
7. HDL-C             Phosphotungstate /Magnesium precipitation method. 
8. Glucose            Glucose-oxidase/ peroxidase method. 
 
B. CALCULATED PARAMETERS 
1. LDL-C and VLDL-C were calculated using Freidwald’s  formula: 
VLDL-C = TGL/5 
    LDL-C = TC-{HDL-C+VLDL-C} 
                2. Creatinine clearance was calculated using Cockcroft- Gault formula                 
                                  (140-age)X wt in kg 
Estimated Creatinine Clearance =________________ 
                                                     72Xserum Creatinine 
 
Multiply by 0.85 for females.                                            
 
ESTIMATION OF SERUM VISFATIN 
Method: 
Enzyme Immuno Assay Kit Purchased from Ray-Biotech. Inc 
 
Principle: 
          Anti-rabbit secondary antibody is precoated onto a micro-titer plate. After 
a blocking step and incubation of the plate with anti-Visfatin antibody, 
Biotinylated Visfatin and standard Visfatin (or) sample are added to all wells. 
There is a competitive binding between biotinylated Visfatin and standard (or) 
serum Visfatin with anti-Visfatin antibody. Streptavidin – Horseradish 
Peroxidase (HRP)was added to the well which reacts with the uncompleted (or) 
      
free biotinylated Visfatin to produce a colour. The Intensity of the colour is 
directly proportional to the amount of biotinylated Visfatin and inversely 
proportional to the amount of Visfatin peptide in the standard or sample. The 
concentration of Visfatin in the serum is calculated from a standard curve of 
different Visfatin concentrations accordingly. 
REAGENTS: 
1. Visfatin Microtiter plate : 96 wells coated with secondary antibody. 
2. Lyophilized  standard  Visfatin  peptide - 2 vials 
3. Lyophilized  anti-Visfatin  polyclonal  antibody – 2 vials 
4. Lyophilized  biotinylated  Visfatin  peptide – 2 vials 
5. Lyophilized  positive  control – 1 vials  
6. IX Assay Diluent  for  both  standard  and  samples. 
7. HRP – streptavidin  concentrate :  600ml 
8. Wash  buffer  concentrate 20X :  25ml 
9. Tetra methyl Benzidine (TMB) one step substrate reagent 12ml  of                                  
3,3’, 5, 5’ Tetra Methyl Benzidine in buffered solution. 
10. Stop solution : 8ml of 0.2M sulphuric acid. 
 
 
Reagent Preparation: 
1. Kit reagents were kept on ice during reagent preparation. 
2. Preparation of  anti-Visfatin  antibody 
      
     AntiVisfatin antibody vial was briefly centrifuged and reconstituted with 5µl 
of deionised water. Then 50µl of IX Assay diluents was added to prepare a 
detection antibody concentrate. Then it was diluted 100 fold with IX Assay 
diluents to get antiVisfatin antibody working solution. 
1. Preparation  of  Biotinylated  Visfatin 
   Biotinylated Visfatin vial was briefly centrifuged and reconstituted with 20µl 
of deionised water before use. Then 5µl of this was added to 5ml of  IX Assay 
diluents  to  get  biotinylated  Visfatin of 10 ng/ml  final concentration. 
2. Preparation of 10 fold dilution of Biotinylated Visfatin: 
   2µl of reconstituted Biotinylated Visfatin was mixed with 18µl of IX Assay 
diluents to get 10 fold dilution of Biotinylated Visfatin. This was used for 
positive control preparation and sample preparation. 
3. Positive control Preparation: 
   Positive control vial was briefly centrifuged and reconstituted with 100µl of 
deionised water. To this 101µl of IX Assay diluent and 2 µl of 10 fold diluted 
Biotinylated Visfatin were added and mixed up. This is the two fold dilution of 
positive control. 
 
 
4. Sample Preparation 
      
   2.5µl of 10 fold diluted Biotinylated Visfatin and 247.5µl of sample was 
mixed so that the final concentration of biotinylated Visfatin concentration 
should be 10ng/dl in each sample. 
5. Preparation of Standards: 
   6 micro-tubes were labeled with the following concentrations: 
Tube no 1  100ng/ml 
Tube no 2  10ng/ml 
Tube no3  1ng/ml 
Tube no 4  100pg/ml 
Tube no 5  10pg/ml 
Tube no 6  0pg/ml 
   450µl of biotinylated Visfatin was added to all tubes. In a separate tube, 10 µl 
of standard Visfatin Peptide was added into 990 µl of biotinylated Visfatin 
solution to prepare a 1000 ng/ml standard. This solution served as the Visfatin 
stock solution. From this solution 50µl was added to the tube 1 labeled as 
100ng/ml to get 100ng/ml Visfatin standard which served as the first standard 
solution.This step was repeated after thorough mixing before each transfer with 
each successive concentration, except the last tube preparing a dilution series as 
shown in the illustration below: 
 
 
      
Tube Concentration of 
Standard 
Biotinylated 
Visfatin 
Standard Visfatin 
1 100ng/ml 450µl 50µl of 1000ng/ml 
standard visfatin 
2 10ng/ml 450µl 50µl of tube 1 
3 1ng/ml 450µl 50µl of tube 2 
4 100pg/ml 450µl 50µl of tube 3 
5 10pg/ml 450µl 50µl of tube 4 
6 0pg/ml 450µl - 
 
 
   The final tube served as the Zero standard (or) total binding the concentration 
of which is 0pg/ml of visfatin. The Concentration of Biotinylated Visfatin is all 
tubes should be 10ng/ml. 
 
 
      
 
6. Wash buffer Preparations 
   20X wash concentration contains visible crystals, which was brought to room 
temperature and mixed gently until dissolved. Then 375ml of Deionised water 
was added to yield 400ml of IX wash buffer. 
 
6. Preparation of HRP – Streptavidin: 
   HRP – streptavidin vial was briefly centrifuged. Then it was diluted 100 fold 
with IX Assay diluent. 
Assay Procedure: 
1. Micro-titre plate was equilibrated to room temperature before opening the 
sealed pouch. 
2. 100µl of anti Visfatin antibody was added into each well. Then the plate 
was incubated for 1.5 hours at room temperature with gentle shaking (1-2 
cycles/sec.) 
3. After incubation the solution was discarded and wells were washed 4 
times with IX wash buffer of 300µl each well using an automated plate 
washer. Then the plate was inverted and blotted against clean paper 
towels. 
4. 100µl of each standard positive control and sample was added into 
appropriate wells. Then the wells were covered and incubated overnight 
at 4⁰ c. 
      
5. After Incubation the solution was discarded and washed 4 times with 
wash buffer. 
6. 100µl of prepared HRP-streptavidin solution was added to each well and 
incubated for 45min with gentle shaking at room temperature. 
7. After Incubation the solution is discarded and washed 4 times with wash 
buffer. 
8. 100µl of TMB substrate was added to each well and incubated for 30 min 
at room temperature in the dark with gentle shaking (1-2 cycles/sec.) 
9. 50µl of stop solution was added and absorbancy was read at 450nm 
immediately. 
 
Calibration Graph: 
   By plotting the mean absorbance of each standard on the y-axis against the 
concentration of Visfatin (ng/ml) in each standard on the x-axis, a calibration 
curve was constructed. 
      
 
    
Sensitivity: 
      The minimum detectable concentration of Visfatin is 379pg/ml . 
Linearity: 
   The linearity of serum Visfatin lies between 1 -100ng /ml. 
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ESTIMATION OF SERUM hs-CRP: 
 
METHOD: 
         Turbidimetric Immuno Assay 
 
PRINCIPLE: 
           Serum C-reactive protein causes agglutination of the latex particles 
washed with Antihuman C-reactive protein. The latex agglutination is 
proportional to the concentration of CRP and can be measured by turbidimetry. 
 
Reagents required: 
1. hsCRP standard 13.8mg/L 
2. Reagent A: Glycine buffer 0.1mol/L, Sodium Azide 0.95g/L, pH 8.6 
3. Reagent B: Suspension of latex particles coated with Anti-human CRP 
antibodies, Sodium Azide 0.95g/L 
 
Reagent Preparation 
   hs CRP standard was prepared by reconstituting it with 5ml of distilled water 
to get a stock solution of 13.8mg/L. A dilution series was prepared as follows: 
 
      
Standard tubes Normal saline(µl ) Volume of hs-
CRP standard 
(µl) 
Concentration of 
hs-CRP standard 
(mg/L) 
1 __ 100µl of stock 13.8 
2 100µl 100µl of stock 6.9 
3 100µl 100µl of tube 2 3.45 
4 100µl 100µl of tube 3 1.725 
5 100µl 100µl of tube 4 0.86 
6 100µl 100µl of tube 5 0.43 
           7 100µl - 0 
 
PROCEDURE: 
   Reagents and samples were brought to room temperature prior to use. 
1. Zero correction of the instrument was done with distilled water. 
2. Working reagent 1.5ml was pipetted into the cuvette, to which either standard 
(or) sample 20µl was added and mixed up. 
3. Then the cuvette was inserted into the instrument immediately. 
4. Absorbance was recorded at 540nm after 10seconds (A1) and after 5 
minutes(A2) 
Calibration: 
         The difference in the Absorbance (A2-A1) for each standard was 
calculated and plotted in y-axis against the corresponding standard hs-CRP 
concentration in the x-axis. Thus the calibration graph was constructed. The hs-
      
CRP concentration in the sample was calculated by interpolation of its 
absorbance (A2-A1)  in  
calibration graph. 
 
 
Detection limit: 
 Minimum detection level is 0.06mg/L 
Measurement Interval: 
 Measurement Interval lies between 0.06-15mg/L 
Reference Values: 
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hs CRP Concentration in mg/L 
Calibration  Graph  of  hsCRP   
      
      
Age hs CRP(mg/L) 
5-13 yrs <1.4 
14-18 <2.13 
19-39 <2.68 
40-49 <4.8 
50-64 <7.9 
65-99 <6.8 
Women  
Age Hs CRP(mg/L) 
5-18 yrs <1.9 
19-49 <3.33 
50-64 <8.5 
65-99 <6.6 
 
 
 
       
 
 
 
      
 
 
ESTIMATION OF UREA 
Method: 
Urease – GLDH method 
Principle: 
   Urea is hydrolyzed to ammonia and carbon dioxide by Urease. Then 
Glutamate dehydrogenase (GLDH) converts Ammonia and α Keto glutarate to 
Glutamate and water with the concurrent oxidation of NADH to NAD
+ 
. Two 
moles of NADH are oxidized for each mole of urea present. 
 
 Urea + H2O 
      
      2NH4
+
 + CO2 . 
      NH4
+
 + NADH + H
+
 + 2-oxoglutarate 
    
     Glutamate + NAD+. 
  
   The initial rate of decrease in absorbance at 340nm is proportional to the Urea 
concentration in the sample. 
Reagent composition: 
Reagent 1: 
       α-Keto Glutaric Acid 99.8mmol/L 
       Urease 23.5kU/L, GLDH 3.5KU/L, Adenosine diphosphate   
       7.6mmol/L, Sodium Azide 0.2%. 
 
      
Reagent 2:   
        NADH 2.95mmol/L, sodium Azide 0.1%  
 Concentration of Urea standard    50mg/dl. 
Reagent Preparation: 
 Working reagent was prepared by mixing 4 parts of reagent 1 
with one part of reagent 2. 
Procedure: 
 3 test tube were labeled as Blank, standard and test and the 
procedure is done as follows: 
Tubes Working 
reagent 
Standard Test sample Distilled 
water 
Blank 1000µl - - 10µl 
Standard 1000µl 10µl - - 
Test 1000µl - 10µl - 
 
 
 The tubes were mixed well and the absorbance was read after 
20 seconds (A1) and 60 sec (A2) at 340nm. 
Calculation: 
∆A = A2 – A1.  
Urea in mg/dl = ∆A of test   × Concentration of standard 
                       ∆A of standard  
 
      
Linearity: 
 The method is linear upto 200mg/dl. 
Reference Interval:  
 Adults  15-30mg/dl. 
ESTIMATION OF SERUM CREATININE 
Method:   
 Modified Jaffe’s Method. 
Principle:   
 Creatinine reacts with alkaline picrate to produce an orange-yellow 
colour. The intensity of the colour is directly proportional to the 
concentration of Creatinine and is measured photometrically at 
510nm. 
Reagent Composition  
Reagent No Composition Concentration 
1 Picric acid 25.8mmol/L 
2 Sodium hydroxide 95mmol/L 
   
   
   
Concentration of standard creatinine 2 mg/dl 
 
      
Reagent Preparation 
 Equal Volumes of reagent 1 and reagent 2 were mixed and 
waited for 15 minutes before use. 
Procedure 
 3 test tubes were taken and labeled as Blank, Standard and 
test and the procedure was done as follows: 
Tubes Working 
reagent 
Standard Test sample Distilled 
water 
Blank 1000µl - - 100µl 
Standard 1000µl 100µl - - 
Test 1000µl - 100µl - 
 
 
 The tubes were mixed well and the absorbance was read after 
20 seconds (A1) and 80 sec (A2) at 510nm, against reagent blank with distilled 
water. 
Calculation 
     ∆A= A2 – A1.                           
Serum Creatinine (mg/dl) =  ∆A of test     ×  Concentration of standard  
                                          ∆A of standard                  
Linearity 
This assay is linear upto 20mg/dl. 
 
      
Reference Range 
 Males:   0.7-1.4 mg/dl 
 Females:   0.6-1.2mg/dl.  
ESTIMATION OF TOTAL CHOLESTEROL: 
Method:   
 Cholestrol Oxidase – PAP method, End Point Analysis. 
Principle: 
1.Cholestrol Ester + Water 
        
        Cholestrol + fatty acid             
2.Cholesterol + oxygen 
                  
                 Cholest – 4- en-3 one + H2O2 
3. 2H2O2 +  4AAP + Phenol
           
          Quinoneimine dye + 4 H2O 
  4AAP - 4 Amino antipyrine 
           Absorbance of quinoneimine is directly proportional to cholesterol 
concentration. 
Reagent composition: 
Goods buffer (PH 6.4) : 100mmol/L 
Cholesterol Oxidase : >100U/L 
Cholesterol Esterase : >200U/L 
Peroxidase        : >3000 U/L 
4- Amino anti pyrine : 0.3mmol/L 
Phenol   : 5mmol/L 
 
      
Procedure: 
Reagents Blank Standard Sample 
Working 
reagent 
1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
 
 The tube were mixed well and incubated for 10min at room temperature. 
The absorbance of the test and standard were read against reagent blank at 
505nm. 
Calculation: 
Cholesterol in mg/dl = ∆A of test × Concentration of standard (mg/dl). 
                                 ∆A of standard 
 
Concentration of cholesterol standard 200mg/dl. 
Reference Range 
AGE  SERUM CHOLESTEROL(mg/dl) 
2-12 months 60-190 
≥1year 110-230 
Adults <200 
 
 
      
 
Linearity: 
This method is linear upto 700mg/dl 
 
ESTIMATION OF TRIGLYCERIDES 
Method:  
Enzymatic method with glycerol Phosphate oxidase (GPO – PAP 
method) 
Principle: 
Triglycerides + H2O 
      
      Glycerol + free fatty acids                 
 
Glycerol + ATP 
               
    
             Glycerol 3 Phosphate + ADP 
              
Glycerol 3 Phosphate + O2 
   
    DAP + H2O2 
    
ATP – Adenosine Triphosphate, 4 AAP 4 Amino Antipyrine,  
DHBS—3,5 Dichloro 2-Hydroxy Benzene Sulfonate 
The Intensity of the Quinoneimine dye formed is proportional to the 
Triglyceride concentration in the sample when measured at 540nm. 
 
 
      
Reagent Composition: 
Reagent 1 (Enzymes/Chromogen): 
Lipoprotein lipase 4000U/L 
4-Amino 
Antipyrine 
0.4 mmol/L 
ATP 2 mmol/L 
Glycerol Kinase 1500U/L 
Peroxidase 2200U/L 
Glycerol Phosphate 
Oxidase 
4000U/L 
 
Reagent – 2: 
Pipes buffer pH7.0: 40mmol/L 
DHBS : 0.2 mmol/L 
Magnesium salt: 2.5 mmol/L 
Working Reagent Preparation: 
 The working reagent was prepared by mixing 4 parts of R1 with 1 part of 
R2, and is stable for 90 days at 2-8
0
C. 
Procedure: 
 Three test tubes were taken and labeled as Blank (B), Test (T) and 
Standard (S). The procedure was as follows: 
 
      
 
Reagents Blank Standard Sample 
Working 
reagent 
1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample -  10µl 
 
The tubes were mixed and incubated for 10 minutes. Absorbance was 
read at 540nm for standard and sample against reagent blank. 
 
Calculation: 
Triglycerides (mg/dl) = Absorbance of test × concentration of standard (mg/dl) 
                                   Absorbance of standard  
Reference Values:  25-160mg/dl 
Linearity: Upto 1000mg/dl 
  
  
  
  
      
  
  
  
  
  
  
  
HDL CHOLESTEROL ESTIMATION 
Method:  
Phosphotungstic acid / Magnesium Precipitation method. 
Principle: 
 Chycomicrons, VLDL-C and LDL-C are precipitated from the serum by 
phosphotungstate in the presence of divalent cations such as Magnesium. The 
HDL cholesterol remains unaffected in the supernatant and is estimated using 
cholesterol reagent 
 
Serum  
              
                HDL-C    +    {LDL-C+VLDL–C+ Chylomiorons} 
                                   (Supernatant)     ( Precipitate) 
 
Reagent Composition: 
Precipitating reagent: 
      
                                                                                                                
 
 
HDL Cholesterol standard  25mg/dl. 
Precipitation: 
 Precipitation of LDL-C, VLDL-C and chylomicrons were done by adding 
500µl of precipitating reagent into 250µl of serum. The tube was mixed well 
and allowed to stand for 10 min. Then it was centrifuged at 3000 rpm for 10 
min and a clear supernatant was obtained. The supernatant was used to 
determine the concentration of HDL cholesterol in the sample. 
Procedure: 
Reagents Blank Standard Sample 
Cholesterol 
working 
reagent 
1000µl 1000µl 1000µl 
Distilled water 50µl - - 
Standard - 50µl - 
Supernatant - - 50µl 
 
 
Phosphotungstic acid 2.4 mmol/L 
Magnesium Chloride 40 mmol/L 
      
Tubes were mixed well and incubated for 10min at room temperature. 
The absorbance of the standard and the test samples were read at 505nm against 
reagent blank. 
Calculation: 
HDL Cholesterol (mg/dl) = Absorbance of test × concentration of standard ×dilution factor.                
                                    Absorbance of standard 
                       
                          =   Absorbance of test × 25 × 3 
          Absorbance of standard 
Linearity: Upto 125mg/dl 
Normal Values: 
Males: 30-65mg/dl 
Females: 35-80 mg/dl. 
Estimation of Glucose: 
Method:  
 Glucose oxidase – peroxidase (GOD-POD) method. 
Analysis:  
  End Point Analysis 
Principle: 
       Glucose is oxidized to yield gluconic acid and hydrogen peroxide in the 
presence of glucose oxidase. Hydrogen peroxide Oxidatively couples with 4-
amino Antipyrine and phenol to produce red quinoneimine dye in the presence 
of peroxidase. This red dye has maximum absorbance at 505nm. The intensity 
      
of the colour complex is directly proportional to the concentration of glucose in 
specimen. 
D-Glucose + O2 + H2O 
    
   Gluconic acid + H2O2 
H2O2 + 4- Amino Antipyrine + Phenol 
   
    red dye + H2O 
Specimen: 
  Fresh unhemolysed serum 
Assay Procedure: 
 Enzyme reagent and standard were brought to the room 
temperature before performing the assay. 
 
 
 
  
 
 
The tubes were mixed thoroughly and incubated at 37
o
 for 10min. The 
absorbance was read against reagent blank at 505nm. 
 
 
 
 
Reagents Blank Standard Sample 
Glucose enzyme reagent 1000µl 1000µl 1000µl 
Standard - 10µl - 
Sample - - 10µl 
Distilled water 10µl - - 
      
Calculation: 
 
Glucose (mg/dl) = Absorbance of test × Concentration of standard (mg/dl) 
                          Absorbance of standard 
Glucose Standard: 100mg/dl 
Linearity:  Upto 500mg/dl  
Normal Values: 
Glucose fasting: 65-100mg/dl 
Glucose postprandial: 90-140mg/dl 
 
 
 
 
 
 
 
 
 
 
 
      
RESULTS 
        A total of 100 subjects were selected as the study group for the present 
study. This includes 50 cases with CKD and 50 healthy controls. 
        Levels of serum Visfatin, Urea, Creatinine , hs CRP, TC, TGL, HDL-C 
and FBG were estimated for all the samples of the study group. VLDL-C, LDL-
C and Creatinine clearance were calculated from the formula. 
       The values obtained in controls and cases are presented in the master chart I 
and II respectively. 
 
 
 
 
                                                                                                      
MASTER CHART – I CONTROL GROUP 
NO SEX AGE 
(Yrs) 
HT 
(m) 
WT 
(Kg) 
BMI 
(Kg/m2) 
SBP 
(mm/Hg) 
DBP 
(mm/Hg) 
FBG 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
CCR 
(ml/min) 
hsCRP 
(mg/L) 
TC 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
VISFATIN 
(ng/ml) 
1 M 38 1.68 62 36.90 110 70 86 20 1 87.83 0.83 168 110 42 22 104 9.8 
2 M 31 1.64 68 41.46 104 80 90 22 1.1 93.58 0.29 186 150 46 30 110 10.2 
3 M 37 1.6 72 45 120 76 80 18 0.9 114.44 0.21 164 122 46 24.4 93.6 8.9 
4 M 35 1.56 66 42.30 90 70 98 28 0.9 106.94 0.58 150 112 45 22.4 82.6 11.2 
5 M 37 1.7 70 41.17 110 80 100 20 1.1 91.03 0.81 180 135 42 27 111 11 
6 M 26 1.68 68 40.47 114 70 102 24 0.8 134.58 0.46 174 140 40 28 106 10.2 
7 M 32 1.7 65 38.23 100 80 78 24 0.8 121.87 0.89 150 124 38 24.8 87.2 8.8 
8 M 33 1.56 67 42.94 96 80 82 18 0.9 110.63 0.33 160 150 46 30 84 10.2 
9 M 35 1.65 55 33.33 112 74 96 26 0.8 100.26 0.42 176 142 42 28.4 106 10 
10 M 34 1.62 68 41.97 98 80 72 20 1 100.11 0.22 178 135 50 27 101 9.1 
11 M 36 1.65 60 36.36 120 76 78 20 0.9 96.29 0.56 184 140 40 28 116 8.8 
12 M 38 1.68 67 39.88 116 70 100 22 1 94.91 0.92 160 138 45 27.6 87.4 8.9 
13 M 36 1.56 65 41.66 90 80 104 28 1 93.88 0.18 208 122 41 24.4 143 8.8 
14 M 28 1.65 56 33.93 118 78 84 20 0.9 96.79 0.67 188 120 40 24 124 10 
15 M 58 1.69 68 40.23 110 70 90 26 0.8 96.8 0.72 175 154 48 30.8 96.2 11 
16 M 68 1.68 73 43.45 100 76 86 26 0.8 91.25 0.32 182 160 44 32 106 8.9 
17 M 64 1.58 69 43.67 96 74 92 24 0.8 91.04 0.88 168 110 42 22 104 8.8 
18 M 61 1.63 60 36.80 126 70 76 24 0.7 94.04 0.41 200 124 45 24.8 130 10 
19 M 62 1.67 68 40.71 90 72 84 28 0.8 92.08 0.29 165 115 42 23 100 11.2 
20 M 53 1.7 68 40 108 80 98 22 0.9 91.29 0.47 152 148 40 29.6 82.4 10.2 
21 M 63 1.52 68 44.73 110 74 86 26 0.8 90.9 0.73 188 134 46 26.8 115 10.5 
22 M 61 1.57 67 42.67 100 70 100 24 0.8 91.89 0.91 164 140 38 28 98 10.7 
23 M 62 1.65 70 42.42 96 72 78 24 0.8 94.79 0.53 166 128 45 25.6 95.4 10 
24 M 61 1.63 72 44.17 94 80 104 20 0.9 87.77 0.25 194 136 40 27.2 127 11 
25 M 62 1.69 68 40.23 106 76 92 18 0.8 92.08 0.36 202 120 36 24 142 10.8 
 
 
 
                                                                                                      
 
 
26 F 31 1.64 68 41.46 104 80 90 22 0.8 109.37 0.29 186 150 46 30 110 10.3 
27 F 37 1.6 72 45 120 76 80 18 0.9 97.27 0.21 164 122 46 24.4 93.6 10.1 
28 F 35 1.56 66 42.30 90 70 98 28 0.8 102.26 0.58 150 112 45 22.4 82.6 10.5 
29 F 26 1.68 68 40.47 114 76 102 24 0.8 114.39 0.48 174 140 40 28 106 11 
30 F 32 1.7 65 38.23 100 70 78 24 0.8 103.59 0.89 150 124 38 24.8 87.2 8.8 
31 F 33 1.56 67 42.94 96 80 82 18 0.9 94.03 0.33 160 150 46 30 84 7.2 
32 F 35 1.56 70 44.87 112 80 96 26 0.8 108.46 0.42 176 142 42 28.4 106 14.1 
33 F 34 1.62 68 41.97 98 74 72 20 0.8 106.36 0.22 178 135 50 27 101 13.2 
34 F 38 1.68 67 39.88 116 76 100 22 0.8 100.85 0.92 160 138 45 27.6 87.4 9.8 
35 F 36 1.56 65 41.66 90 70 104 28 0.8 99.75 0.81 208 122 41 24.4 143 11 
36 F 40 1.56 66 42.30 88 70 74 26 0.8 97.39 0.34 180 108 38 21.6 120.4 13.2 
37 F 42 1.53 63 41.17 108 78 100 24 0.8 91.1 0.63 178 112 46 22.4 110 13.5 
38 F 61 1.57 66 42.03 90 70 82 22 0.6 102.59 0.72 164 110 40 22 102 12 
39 F 46 1.62 65 40.12 106 74 92 28 0.6 120.21 0.28 196 126 45 25.2 126 8.8 
40 F 41 1.62 63 38.88 100 72 94 20 0.8 92.03 0.59 202 148 37 29.6 135 11.2 
41 F 44 1.56 64 41.02 110 82 98 28 0.8 90.66 0.63 180 140 45 28 107 12.3 
42 F 50 1.6 60 37.5 100 78 80 20 0.7 91.07 0.79 172 155 38 31 103 11 
43 F 45 1.57 66 42.03 96 70 72 20 0.8 92.52 0.52 150 142 38 28.4 83.6 10.2 
44 F 52 1.58 62 39.24 98 72 78 28 0.7 92.01 0.83 184 138 46 27.6 110 10.6 
45 F 45 1.55 65 41.93 102 78 90 24 0.8 91.12 0.29 180 168 40 33.6 106 10.2 
46 F 45 1.58 66 41.77 90 70 100 22 0.8 92.52 0.64 166 140 42 28 96 11 
47 F 40 1.53 70 45.75 120 80 78 22 0.9 91.82 0.31 170 134 38 26.8 105 14.3 
48 F 46 1.6 66 41.25 100 74 82 18 0.8 91.55 0.42 194 126 42 25.2 127 11.5 
49 F 41 1.62 63 38.88 100 72 94 20 0.8 92.03 0.59 202 148 37 29.6 135 15 
50 F 28 1.58 62 39.24 98 72 78 28 0.7 117.11 0.83 184 138 46 27.6 110 11.2 
 
MASTER CHART – I CONTROL  GROUP 
 
 
 
                                                                                                      
MASTER CHART – II STUDY GROUP 
S.NO SEX AGE 
(yrs) 
HT 
(m) 
WT 
(Kg) 
BMI 
(Kg/m2) 
SBP 
(mm/Hg) 
DBP 
(mm/Hg) 
FBG 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
CCR 
(ml/min) 
hsCRP 
(mg/L) 
TC 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
Visfatin 
(ng/ml) 
1 M 65 1.53 35 14.95 126 82 120 92 3 12.15 10 180 180 28 36 116 32.2 
2 M 65 1.64 43 15.99 152 84 112 108 3.8 11.79 7.44 150 200 38 40 72 39.6 
3 M 47 1.73 57 19.05 118 80 86 88 2.5 29.45 3.69 174 184 38 36.8 99.2 31 
4 M 55 1.67 65 23.31 114 76 146 92 2.7 28.42 4.53 162 152 34 30.4 97.6 29.6 
5 M 32 1.62 55 20.96 150 100 110 104 3.14 26.27 8.7 182 192 42 38.4 102 28.5 
6 M 75 1.78 60 18.94 150 90 132 96 2.3 23.55 7.61 172 180 46 36 90 26.9 
7 M 73 1.73 52 17.37 120 80 106 90 2.81 17.22 10.4 184 208 32 41.6 110 30.5 
8 M 65 1.67 72 25.82 110 70 72 114 3 25 2.9 176 166 36 33.2 107 28 
9 M 38 1.62 53 20.2 140 70 114 130 4.9 15.32 5.58 172 152 40 30.4 102 31.8 
10 M 35 1.7 86 29.76 124 82 120 126 5.7 22 8.89 160 176 42 35.2 82.8 25.7 
11 M 45 1.63 57 21.45 110 80 112 80 1.6 47.01 3.2 160 184 40 36.8 83.2 20.8 
12 M 45 1.55 62 25.81 110 74 74 88 2.2 37.18 0.69 190 160 33 32 125 22.8 
13 M 32 1.57 50 20.28 160 110 120 90 2 37.5 3.72 174 240 37 48 89 24.2 
14 M 38 1.63 60 22.58 140 100 70 70 1.4 60.71 0.93 174 210 42 42 90 19.5 
15 M 55 1.76 68 21.95 140 100 140 60 1.3 61.75 1.54 180 220 36 44 100 19.2 
16 M 48 1.7 74 25.61 112 80 132 68 1.3 72.74 2.06 166 150 38 31.2 96.8 18.9 
17 M 23 1.66 55 19.96 120 80 74 72 1.4 63.84 1.2 174 198 38 39.6 96.4 19.4 
18 M 48 1.59 76 30.06 140 82 104 64 1.3 74.7 3.13 162 202 34 40.4 87.6 17.5 
19 M 37 1.45 36 17.12 120 80 122 142 8.9 5.78 10.56 216 180 32 36 148 42.5 
20 M 53 1.62 70 26.67 118 74 90 136 8.3 10.19 9.7 160 170 36 34 90 40.5 
21 M 57 1.55 58 24.14 124 80 106 128 4.9 13.65 6.91 220 208 28 41.6 150 39.6 
22 M 45 1.6 48 18.75 128 86 142 110 4.3 14.73 6.73 170 216 40 43.2 86.8 39 
23 M 53 1.57 62 25.15 170 100 92 134 7.8 9.27 5.82 166 192 32 38.4 95.6 39 
 
 
 
                                                                                                      
24 M 45 1.62 45 17.15 130 70 116 90 1.94 30.61 2.99 160 230 35 46 79 31 
25 M 55 1.7 55 19.03 110 80 130 110 2.03 31.99 3.96 196 160 38 32 126 31.2 
26 F 58 1.54 44 18.55 110 80 128 78 1.3 27.84 2.97 178 154 4 30.8 102 31.6 
27 F 49 1.56 68 27.94 126 82 80 84 1.9 32.68 3.98 160 170 37 34 89 22.1 
28 F 54 1.52 65 28.13 170 100 112 70 1.56 35.95 2.63 150 168 42 33.6 74.4 18.9 
29 F 70 1.59 75 29.67 102 90 86 68 1.8 29.26 3.7 172 208 40 41.6 90.4 19.9 
30 F 33 1.55 45 18.73 120 80 74 74 1.6 30.2 4.67 184 176 34 35.2 115 20 
31 F 58 1.62 55 20.96 124 72 72 80 1.4 32.32 5.3 160 188 34 37.6 88.4 21.5 
32 F 55 1.56 45 18.49 130 80 110 92 2.69 14.27 8.6 162 200 35 40 87 33.2 
33 F 55 1.5 40 17.78 120 80 80 86 1.7 20.66 5 170 194 28 38.8 103 25.7 
34 F 57 1.56 60 24.65 114 72 128 98 2.9 17.22 4.93 192 168 46 33.6 112 29.1 
35 F 63 1.61 46 17.75 156 90 136 130 4.6 7.72 4.89 208 192 28 38.4 142 42 
36 F 53 1.54 47 19.82 160 92 70 148 58 7.07 5.6 200 184 40 36.8 123 41.8 
37 F 50 1.57 52 21.1 150 100 102 126 4.7 9.99 8.26 186 178 34 35.6 116 40.6 
38 F 48 1.54 45 18.97 120 80 76 150 7.3 5.69 2.15 152 190 37 38 77 42.8 
39 F 61 1.5 43 19.11 110 80 110 134 5.3 6.42 9.8 176 184 48 36.8 91.2 41.7 
40 F 62 1.66 56 20.32 114 82 90 104 2.2 19.92 10.9 170 212 46 42.4 81.6 25.7 
41 F 57 1.7 68 23.53 130 80 138 110 2.5 22.65 9.26 162 168 38 33.6 90.4 33.5 
42 F 42 1.61 68 26.23 110 80 72 68 1.3 51.44 1.73 174 134 40 26.8 107 19.5 
43 F 33 1.67 67 24.02 120 84 86 80 1.4 51.38 4.92 198 140 45 28 125 19.7 
44 F 37 1.7 70 23.53 110 80 100 56 1.1 77.38 1.81 180 135 42 27 111 15.5 
45 F 61 1.63 72 27.1 120 72 104 66 0.9 74.61 1.07 216 180 32 36 148 16.4 
46 F 45 1.7 62 21.45 140 100 70 70 0.9 77.26 0.93 174 210 42 42 90 16.5 
47 F 62 1.69 68 23.81 150 100 140 60 0.8 78.26 1.54 180 220 36 44 100 15.2 
48 F 48 1.7 74 25.61 112 80 132 68 1.3 61.82 2.06 166 156 38 31.2 96.8 19.4 
 
 
 
                                                                                                      
49 F 35 1.68 73 25.86 120 80 74 72 1.3 69.6 1.2 174 198 38 39.6 96.4 14.7 
50 F 63 1.58 68 27.24 140 82 104 64 0.8 77.26 3.13 162 202 34 40.4 87.6 15.5 
 STATISTICAL ANALYSIS 
 Student’s t-test, Chi-square test and oneway ANOVA were used for the 
statistical analysis of data. 
 The datas were expressed in terms of mean and standard deviation. 
 ‘p’ value less than 0.05 was taken as the significant value. 
 Correlation between the measured parameters was assessed using 
Pearson’s correlation coefficient. 
 
 
 
 
 
 
 
 
 
 
 Table 1 represents the minimum level, maximum level, mean and SD of all 
parameters of the study group. 
DESCRIPTIVE STATISTICS OF THE STUDY GROUP. 
S.NO PARAMETERS CONTROLS( n=50) CASES (n=50) 
MIN MAX MEAN SD MIN MAX MEAN SD 
1 Age (years) 
 
26 68 43.08 11.83 23 75 50.76 11.74 
2 Height (m) 
 
1.52 1.7 1.61 0.05 1.45 1.78 1.61 0.73 
3 Weight(kg) 
 
55 73 66.06 3.76 35 86 58.6 11.83 
4 BMI (kg/m
2
) 
 
20.2 29.9 25.39 2.18 14.9 30.06 22.26 3.93 
5 SBP(mm/Hg) 
 
88 126 103.6 9.95 102 170 125.68 24.1 
6 DBP (mm/Hg) 
 
70 82 74.84 4.04 70 110 83.76 9.59 
7 FBG (mg/dl) 
 
72 104 88.6 9.95 70 146 104.32 23.64 
8 Blood Urea 
(mg/dl) 
18 28 23.04 3.38 56 150 94.36 26.33 
9 s. Creatinine 
(mg/dl) 
0.6 1.1 0.83 0.1 0.8 8.9 2.87 2.05 
10 Ccr(ml/min) 
 
87.77 134.58 98.78 10.1 5.78 78.27 35.91 23.52 
11 s.hsCRP (mg/L) 
 
0.18 0.92 0.53 0.23 0.69 10.56 4.54 2.96 
12 S.TC(mg/dl) 
 
150 208 173 28.2 150 220 175.72 16.49 
13 S.TGL (mg/dl) 
 
108 168 133.54 14.57 134 216 171.86 23 
14 S.HDL-
C(mg/dl) 
36 50 42.52 3.55 24 45 33.84 7.06 
15 S.VLDL-
C(mg/dl) 
21.6 33.6 25.86 5.59 26.8 43.2 34.37 4.6 
16
 
Serum LDL-C 
(mg/dl) 
82.4 143 106.56 16.71 78.4 150.4 107.5 16.54 
17 S.Visfatin 
( ng/ml) 
7.2 15 10.62 1.57 14.7 42.8 27.42 8.92 
 
 
 
 
 Table 2 
GENDERWISE DISTRIBUTION OF THE STUDY GROUP AND 
STATISTICAL ANALYSIS 
 
The distribution of males and females in the study group were 50% and 50% 
respectively which shows equal distribution .There is no significant difference 
in gender between cases and controls. 
 
 
 
 
 
 
 
GROUPS GENDER STATISTICAL 
INFERENCE MALES (%) FEMALES(%) 
CONTROLS 
( n=50) 
n=25 
(50%) 
n=25 
(50%) 
 
X
2
 = 16.430; 
 
p value >0.05 
 
not significant. 
CASES (n=50) n=25 
(50%) 
n=25 
(50%) 
 
TOTAL n=50 
(50%) 
n=50 
(50%) 
 
 Table 3 
AGE WISE DISTRIBUTION OF THE STUDY GROUP 
GROUPS AGE (YEARS) MEDIAN 
AGE 
(YEARS) 
RANGE 
(YEARS) MEAN SD 
CASES 50.76 
 
11.89 50 23-75 
CONTROLS 47.85 
 
10.55 46.5 26-68 
 
 The age group of cases ranged from 23-75 years with a mean age of 
50.76±11.89 years and median age of 50 years. The age group of controls 
ranged from 26-68 years, with the mean age of 47.85±10.55 years and median 
age of 46.5 years. 
 
 
 
 
 
 
 
 
 Table 4 
COMPARISON OF SERUM VISFATIN LEVEL IN THE STUDY 
GROUP 
S.NO GROUPS SERUM VISFATIN 
(NG/ML) 
STATISTICAL 
INFERENCE 
MEAN SD 
1 Controls (n=50) 
 
10.62 1.57 t=13.11; 
 P<0.05 
significant 2 Cases (n=50) 
 
27.42 8.92 
 
The mean value of Visfatin in cases was 27.42±8.92 ng/ml and this was 
significantly higher than that of the control group whose mean value was 
10.62±1.57 ng/ml (t=13.11; p<0.05 significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5  
AGE MATCHED ANALYSIS OF SERUM VISFATIN LEVEL IN THE 
STUDY GROUP 
AGE ( Yrs) SERUM VISFATIN( ng/ml) STATISTICAL 
INFERENCE GROUPS MEAN SD 
< 30 Controls (n=4) 
 
10.6 0.58 t=12.358 
p <0.05 
significant Cases (n=2) 
 
19.7 0.42 
31-40 Controls(n=23) 
 
10.35 1.82 t=7.577 
P <0.05 
Significant Cases (n=9) 
 
24.67 8.80 
41-50 Controls(n=10) 
 
11.47 1.76 t=4.888 
P <0.05 
Significant Cases (n=13) 
 
26.3 9.41 
51-60 Controls (n=3) 
 
10.6 0.40 t=4.493 
p<0.05 
significant 
 
Cases (n=14) 
 
31.02 7.67 
>60 Controls(n=10) 
 
10.39 0.99 t=5.54 
P <0.05 
Significant Cases (n=12) 
 
27.8 9.85 
 
 
 This table shows the comparision of serum Visfatin level in various age 
groups in the study subjects. Serum Visfatin is significantly higher in the cases 
than controls in all the included age groups. 
 
 
 
 Table 6  
GENDER MATCHED COMPARISON OF SERUM VISFATIN LEVELS 
IN THE STUDY GROUP 
 
GENDER GROUPS SERUM VISFATIN 
(ng/ml) 
STATISTICAL 
INFERENCE 
MEAN SD 
Males Control(n=25) 
 
9.96 0.85 t=12.358 
P<0.05 
significant Cases (n=25) 
 
29.15 7.71 
Females Control(n=25) 
 
11.28 1.84 t=7.197 
P<0.05 
significant Cases (n=25) 
 
25.70 9.84 
 
 This table represent the gender-wise comparison of serum Visfatin in 
controls [ males: mean 9.96±0.85, females: mean 11.28± 1.84] and cases 
[males: mean 29.15±7.71, females 25.7±9.84]. Serum Visfatin is significantly 
higher in both sexes of cases than in controls (P<0.05). 
 
 
 
 
 
 
 
 
 Table 7 
GENDERWISE COMPARISON OF SERUM VISFATIN IN CASES 
 
S.NO GENDER SERUM 
VISFATIN(ng/ml) 
STATISTICAL 
INFERENCE 
MEAN SD 
1 Males(n=25) 
 
29.15 7.71 t=1.389 
p>0.05 not 
significant 2 Females(n=25) 
 
25.70 9.84 
 
 
 This table shows the gender wise comparison of serum Visfatin level within 
cases [males:mean 29.15±7.71; females 25.7±9.84]. There is no significant 
difference of serum Visfatin level between genders in the cases (T = 1.389 ; 
p>0.05). 
 
 
 
 
 
 
 
 Table 8  
COMPARISON OF FBG, BLOOD UREA, SERUM CREATININE AND 
CREATININE CLEARANCE IN THE STUDY GROUP 
PARAMETERS GROUPS MEAN SD STATISTICAL 
INFERENCE 
FBG(mg/dl) Cases(n=50) 
 
104.32 23.64 t=4.332 
P<0.05 
significant Control(n=50) 
 
88.6 9.95 
B.Urea(mg/dl) Cases(n=50) 
 
94.36 26.33 t=19.00 
P<0.05 
significant Control(n=50) 
 
23.04 3.33 
 
Creatinine(mg/dl) 
Cases(n=50) 
 
2.87 2.05 t=6.999 
P<0.05 
significant Control(n=50) 
 
0.83 0.10 
Ccr(ml/min) Cases(n=50) 
 
35.91 23.51 t=17.363 
P<0.05 
significant Control(n=50) 
 
98.78 10.10 
 
There is a significant difference in FBG between the two groups (T= 
4.332, p<0.05).FBG is significantly higher in cases than in controls indicates 
CKD is prevalent in DM. Blood urea and Serum Creatinine were found to be 
significantly higher in cases and Ccr was significantly lower in the cases than 
controls (p <0.05, significant). 
 
 
 
 
 
 Table 9 
COMPARISON OF SERUM hsCRP IN THE STUDY GROUP 
PARAMETERS GROUPS MEAN SD STATISTICAL 
INFERENCE 
 
s.hsCRP(mg/L) 
Controls(n=50) 
 
0.53 0.23 t=9.514; 
 P<0.05 
Not significant Cases(n=50) 
 
5.54 2.96 
 
 From this table it is obvious that hsCRP level was significantly higher in 
the cases than controls (p<0.05, significant).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 10 
COMPARISON OF LIPID PARAMETERS IN THE STUDY GROUP 
PARAMETERS GROUPS MEAN SD STATISTICAL 
INFERENCE 
TC (mg/dl ) Cases(n=50) 
 
175.72 16.492 t=0.589; 
P>0.05 
not significant Controls(n=50) 
 
173.00 28.202 
TGL(mg/dl ) Cases(n=50) 
 
171.86 23.005 t=9.951; 
P<0.05 
significant Controls(n=50) 
 
133.54 14.570 
HDL-C (mg/dl ) Cases(n=50) 
 
33.84 7.061 t=7.765; 
P<0.05 
significant Controls(n=50) 
 
42.52 3.553 
VLDL-C 
(mg/dl) 
 
 
Cases(n=50) 
 
34.372 4.600 t=8.301; 
P<0.05 
significant 
 
Controls(n=50) 
 
25.868 5.5957 
LDL-C(mg/dl ) Cases(n=50) 
 
107.5080 16.5463 t=0.284; 
P>0.05 
Not significant Controls(n=50) 
 
106.5640 16.7122 
 
We observed a significantly higher serum TGL and VLDL-C levels and a 
significantly lower HDL-C levels in the cases than controls (p<0.05). There is 
no significant difference in the serum TC and LDL-C levels between the two 
groups. 
 
 
 
 Table 11COMPARISON OF VISFATIN IN RELATION TO CCR IN 
CASES. 
 
 
 
 
 
 
 
      
As the Creatinine clearance declines, we observed a significant 
progressive increase in the serum Visfatin levels in cases ( p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
Ccr 
(ml/min) 
VISFATIN 
( ng/ml) 
STATISTICAL 
INFERENCE 
MEAN SD 
60-90 
(n=14) 
17.63 
 
1.92 
 
 
F=102.921; 
P<0.05 
Significant 
30-59 
(n=12) 
24.58 
 
5.08 
 
15-29 
(n=12) 
29.06 
 
2.80 
 
<15 
(n=12) 
40.10 2.82 
 
 Table 12COMPARISON OF hsCRP IN RELATION TO Ccr IN CASES 
 
 
 
 
 
 
 
 
This table represents the comparision of serum hsCRP levels in the study 
group in relation to Ccr. We observed a significant progressive increase in the 
hs CRP value in the cases as the renal function declined ( p<0.05). 
 
 
 
 
 
 
 
 
Ccr 
(ml/min) 
 
hsCRP(mg/L) 
 
STATISTICAL 
INFERENCE 
MEAN SD 
60-90 
(n=14) 
 
1.56 
 
0.58 
 
 
F=43.09; 
 
P<0.05 
 
Significant 
30-59 
(n=12) 
 
2.88 
 
0.90 
 
15-29 
(n=12) 
 
6.73 
 
2.20 
 
<15 
(n=12) 
7.48 2.05 
 Table 13 
COMPARISON OF UREA IN RELATION TO Ccr IN CASES 
 
 
 
 
 
 
 
 
 
 
 
 
This table  represents the comparison of Blood Urea levels in the study 
group in relation to Ccr. There is a significant progressive increase in the Blood 
Urea values with declining renal function in cases (p<0.05). 
 
 
 
 
 
Ccr 
(ml/min) 
 
UREA(mg/dl) 
 
STATISTICAL 
INFERENCE 
Mean SD 
60-90 
(n=14) 
 
67 
 
6 
 
 
F=55.858; 
 
P<0.05 
 
Significant 
30-59 
(n=12) 
 
83.33 
 
11.26 
 
15-29 
(n=12) 
 
103.5 
 
14.145 
 
<15 
(n=12) 
128.17 17.17 
  
 Table 14 COMPARISON OF CREATININE IN RELATION TO Ccr IN 
CASES  
 
 
 
           
 
 
 
 
 
 
 
 
 
 This 
table shows the comparison of serum Creatinine levels in the study group in 
relation to Ccr. We observed a significant progressive increase of Creatinine 
values as the renal function decreases in cases serum Creatinine levels (p<0.05) 
were within normal reference range for controls. 
 
 
 
 
Ccr 
(ml/min) 
 
Creatinine(mg/dl) Statistical 
inference 
Mean SD 
60-90 
(n=14) 
 
1.17 
 
0.22 
 
 
F=41.449; 
 
P<0.05 
 
Significant 
30-59 
(n=12) 
 
1.81 
 
0.34 
15-29 
(n=12) 
 
3.04 
 
1.13 
 
<15 
(n=12) 
5.72 1.9 
 Table 15 
COMPARISON OF LIPID PARAMETERS IN RELATION TO Ccr IN 
THE CASES 
PARAMETERS CREATININE  CLEARANCE 
(ml/min) 
STATISTICAL 
INFERENCE 
60-90 30-50 15-29 <15 
TC (mg/dl)      
Mean 177.14 171.50 172 182.00 F=1.086 
p>0.05 
SD 
 
14.48 13.96 10.05 24.24 Not significant 
TGL(mg/dl)      
Mean 
 
144.07 165.67 180.50 201.83 F=117.907 
P<0.05 
SD 
 
6.00 8.60 6.66 10.49 Significant 
HDL(mg/dl)      
Mean 42.64 35.92 29.83 25.50 F=119.012 
P<0.05 
SD 
 
1.73 2.15 3.76 1.73 Significant 
VLDL(mg/dl)      
Mean 28.81 33.13 36.10 40.36 F=117.907 
P<0.05 
SD 
 
1.20 1.72 1.33 2.09 Significant 
LDL(mg/dl)      
Mean 105.68 102.45 106.06 116.13 F=1.605 
P>0.05 
SD 14.21 14.68 9.00 23.84 Not Significant 
  
Serum TC and LDL-C levels were found to be within the normal 
reference range in the cases irrespective of Ccr. We observed a serial significant 
increase in the serum TGL and VLDL-C levels and a serial significant decrease 
in the HDL-C levels with declining renal function (p<0.05). 
 TABLE 16 
KARL PEARSON COEFFICIENT CORRELATION BETWEEN SERUM 
VISFATIN AND OTHER BIOCHEMICAL PARAMETERS IN CASES 
(n=50) 
S.NO PARAMETERS CORRELATION 
VALUE (r) 
STATISTICAL 
INFERENCE 
1 Urea 0.902(**) p<0.01 ;significant 
2 Creatinine 0.832(**) p<0.01 ;significant 
3 Ccr -0.898(**) p<0.01 ;significant 
4 hsCRP 0.746(**) p<0.01; significant 
5 TC 0.164 p>0.05; NS 
6 TGL 0.877(**) p<0.01; significant 
7 HDL -0.889(**) p<0.01; significant 
8 VLDL 0.877(**) p<0.01; significant 
9 VDL 0.298(**) p<0.05 ;significant 
 
 
This table shows the Pearson’s correlation coefficient between serum 
visfatin and other studied biochemical parameters in the cases. There is highly 
positive correlation of serum Visfatin with hsCRP, Blood Urea, Serum 
Creatinine, TGL and VLDL-C (p<0.01). We also observed a highly negative 
correlation of serum Visfatin with HDL-C and Ccr (p<0.01). 
Figure 5 
Bar diagram showing the serum Visfatin level in the study group. 
 Figure 6 
 Bar diagram showing the comparison of serum hsCRP in the study 
group. 
Figure 7 
Bar diagram showing the comparison of serum Visfatin levels in the 
study group in relation to Creatinine Clearance. 
Figure 8  
Bar diagram showing the comparison of serum hsCRP in the study group 
in relation to Creatinine Clearance. 
Figure 9 
 Scatter diagram of serum Visfatin vs hsCRP in controls. 
Figure 10 
 Scatter diagram of serum Visfatin vs hsCRP in cases. 
Figure 11 
 Scatter diagram of serum Visfatin vs Creatinine Clearance in controls. 
Figure 12 
 Scatter diagram of serum Visfatin vs Creatinine Clearance in cases. 
 Figure 13 
 Scatter diagram of serum Visfatin vs TGL in controls. 
Figure 14 
 Scatter diagram of serum Visfatin vs TGL in cases. 
Figure 15 
 Scatter diagram of serum Visfatin vs HDL-C in controls. 
Figure 16 
 Scatter diagram of serum Visfatin vs HDL-C in cases. 
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                                                              DISCUSSION 
In the present study serum Visfatin concentrations were found to be 
significantly increased in patients with CKD (mean 27.42 ± 8.92) when 
compared to the control group (mean 10.62 ± 1.57). 
 When patients in different stages of CKD were compared, serum Visfatin 
levels were found to be progressively increased from stage 2 to stage 5 in 
comparison with the control group. This observation shows that increase in 
serum Visfatin develops relatively in the early stages of CKD, and is further 
increased with the progression of renal dysfunction and inversely correlated 
with Creatinine clearance ( r = -0.898, p < 0.01 significant). 
 We also observed that serum Visfatin levels were significantly higher in 
all age groups and in both genders when compared to controls which indicates 
that age and gender does not have an impact on serum Visfatin levels. These 
findings are in accordance with the study of Tang et al which reported an 
increase in serum Visfatin levels in all stages of CKD
69
. 
 CKD is a state of chronic persistent low grade subclinical inflammation 
in which there is a chronic systemic elevation of pro-inflammatory mediators 
and cytokines released from adipose tissue. Kidney plays an important role in 
the excretion of adipokines. The decreased renal function in CKD patients leads 
to altered handling of these adipokines causing its accumulation in the body.  
Hence serum Visfatin level is increased in CKD patients. Visfatin plays an 
 important role in innate immunity. It is secreted by activated lymphocytes, 
monocytes and neutrophils and stimulates IL-6 secretion via P38 Mitogen 
Activated Protein Kinase (MAPK) and MAPK Kinase 1 (MEK1) pathways. 
Visfatin also induces the expression of inflammatory mediators in human 
endothelial cells through the NF-κB pathway. Visfatin also stimulates the 
synthesis of CRP which is a positive acute phase reactant through IL-6. The 
prototypic biomarker of inflammation in the clinical setting is hsCRP and its 
higher level is associated with cardiovascular risk in CKD patients. Hence 
Visfatin could play an indirect role in CVD in CKD patients. 
 In the present study we observed a significantly higher levels of serum 
hsCRP in CKD cases when compared to controls [mean value: cases 4.5432 ± 
2.9689; controls 0.5360 ± 0.2343, Pvalue < 0.05].As the renal function declined, 
we observed a progressive increase in the serum hsCRP levels. Further a strong 
positive correlation was found between serum Visfatin and hsCRP levels 
(r=0.746, p<0.01) which shows that increased serum Visfatin stimulates the 
synthesis of CRP from liver. These results of the present study are in 
accordance with that of the previous studies suggesting a global pro-atherogenic 
inflammatory activation occurs even in early stages of CKD leading onto 
upregulation of serum Visfatin. 
 Dyslipidemia, an atherogenic risk factor contributes to the initiation and 
progression of CKD partly by stimulating and amplifying the effect of 
 inflammatory mechanisms. In the present study we observed a significantly 
higher serum TGL and VLDL-C in cases than controls (p < 0.05). There is no 
significant difference of TC and LDL between cases and controls. Furthermore 
we observed a significant positive correlation of serum Visfatin with TGL (r = 
0.877, p<0.01) which is an independent strong predictor of cardio vascular 
events. We also observed a strong negative correlation of serum Visfatin with 
the HDL-C (r = - 0.899, p<0.01) which is considered as an independent strong 
inverse predictor of cardio vascular events. Inflammation and dyslipidemia are 
well known risk factors of atherosclerosis. Visfatin plays a role in linking 
inflammation and lipid dysregulation to atherosclerosis. 
 Previous studies have been demonstrated that increased Visfatin could be 
considered as a marker of endothetial dysfunction to predict the incidence of 
cardiovascular disease in CKD
71
. Kim et al observed the effect of visfatin on 
vascular endothelium. It induces the inflammatory mediators in endothetial cells 
through NF-KB pathway. Visfatin belongs to middle molecule uremic retension 
substance family which induces the leucocyte adhesion to endothelial cells and 
aortic endothelium by induction of cell adhesion molecules such as ICAM -1 
(Intra Cellular Adhesion Molecule -1) and VCAM-1 (Vascular Cell Adhesion 
Molecule -1). Furthermore Visfatin enhances the production of reactive oxygen 
species through NADPH dependent pathway which accelerates vascular 
diseases by causing endothelial dysfunction. Accumulated Visfatin in CKD 
 patients may directly affect the endothelium to cause endothelial dysfunction. In 
addition to that Visfatin enhances the vascular smooth muscle cell proliferation 
and maturation. Taken together Visfatin may be considered as a surrogate 
marker of endothelial dysfunction in CKD patients
72
. This is supported by 
Axelsson et al who observed a positive association between Visfatin and 
endothelial cell adhesion molecule, which is a marker of endothelial 
dysfunction. This finding is further supported by Yilmaz et al who observed 
improvement in endothelial dysfunction by assessing flow mediated 
vasodilatation of the brachial artery during the first month after Renal 
Transplantation and the degree of improvement was correlated with the 
decreasing Visfatin concentration in blood
73
. 
 Taken together the results of the present study suggest that serum Visfatin 
is a novel marker of endothelial dysfunction in CKD patients. Both intra and 
extra cellular Visfatin act as regulator of vascular function. As an intracellular 
form it extents the life span of vascular smooth muscle cells by augmenting 
SIRT-1 mediated p53 degradation. As an extracellular isoform, working in 
NAD dependent fashion ,it enhances the vascular smooth muscle cell 
proliferation and maturation leading on to atherosclerotic changes. It also 
suggests that higher the level of Visfatin the higher the degree of severity of 
CKD. The higher level of Visfatin in CKD is due to either chronic inflammation 
which is associated with this disease (or) hypoxia as a result of tubulonecrosis, 
 anemia and decreased capillary flow. Elevated Visfatin is also associated with 
increased mortality in CKD patients. Hence serum Visfatin could be considered 
as a novel marker of cardiovascular disease in CKD patients to predict 
Premature Atherosclerosis and Death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 The present study demonstrated that serum Visfatin levels are 
significantly increased in patients with CKD. This increase in serum 
Visfatin level is progressive from the early stages to the late stages of 
CKD . 
 The chronic inflammatory state and hypoxia due to tubulonecrosis, 
anemia and decreased capillary flow could be responsible for the 
increased serum Visfatin level in CKD patients. 
 Visfatin causes endothelial dysfunction either directly or indirectly 
suggesting the possible role in the development of coronary 
atherosclerosis. 
 Visfatin may be considered as the novel marker of mortality predictor in 
CKD patients. Higher the visfatin level, higher the mortality of CKD 
patients. 
 
 
 
 
 
 LIMITATIONS OF THE STUDY 
 Application of imaging techniques would have helped us to evaluate flow 
mediated dilatation for endothelial dysfunction and intimal thickness of 
Carotid artery for atherosclerosis. 
 Estimation of other biochemical parameters of endothelial dysfunction 
like Endothelin -1, Thrombomodulin, NO and E-selectin would have 
helped us to assess the degree of endothelial dysfunction & 
atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
 SCOPE FOR FUTURE STUDY 
Inflammation and endothelial dysfunction which are common 
pathological events in Chronic Kidney Disease to develop cardiovascular 
decrease. Hence blocking this novel inflammatory adipokine may be helpful in 
preventing (or) at least delaying the progression of such complications in CKD. 
FK 866 or APO 866 is an inhibitor of Visfatin , which is currently used as an 
anticancer drug. Novel therapeutic approaches targeting Visfatin is the goal of 
future research. 
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  PROFORMA 
SERUM VISFATIN- A NOVEL MARKER IN CHRONIC KIDNEY DISEASE 
 
NAME OF THE PATIENT : 
 
AGE/SEX   :  
 
OCCUPATION  : 
 
ADDRESS   : 
 
COMPLAINTS   :Oliguria/Nocturia/Dysuria/Pedaledema/anasarca/ 
                                                 Fever/ Weight loss 
 
PAST HISTORY  :HT/DM/Tuberculosis/Cerebrovascular disease/liver   
                                                 disease/Rheumatoid arthritis 
PERSONAL HISTORY :Diet/Tobacco/Alcohol/Cigarette use 
 
FAMILY HISTORY  :HT/DM/Renal disease 
 
DRUG HISTORY  : Drugs (lipid lowering drugs, calcium/phosphate   
                                            binders)/renal replacement therapy 
 
 
 
 GENERAL EXAMINATION:          
                                               Ht:                Wt:            BMI:               BP:                 PR: 
SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                           
                                            ABD:                                                  CNS:  
PROVISIONAL DIAGNOSIS:                                                                                    
INVESTIGATIONS : 
1.BLOOD SUGAR(FASTING):                                  
2.BLOOD UREA : 
3.SERUM CREATININE: 
4.CREATININE CLEARANCE: 
5.SERUM VISFATIN: 
6.SERUM hsCRP: 
7.LIPID PROFILE: 
 
TOTAL CHOLESTEROL: 
 
TRIGLYCERIDES: 
HDL: 
 
LDL: 
 
VLDL: 
                                                         CONSENT FORM 
 
 
 Dr.S.SYED ALI FATHIMA, post graduate student in the department of 
Biochemistry, Thanjavur medical college, Thanjavur is doing a Study On Serum  
Visfatin-a novel marker in chronic kidney disease. The procedure has been 
explained to me clearly. I understand that there are no risks involved in the 
above procedures. I hereby give my consent to participate in this study. The 
data obtained here may be used for research and publication. 
 
Signature : 
 
Name: 
 
Place:  
 
 
 
 
                                           
 
